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ABSTRACT 
The purpose of this study was to design, synthesize and develop novel transporter 
targeting agents for image-guided therapy and drug delivery. Two novel agents, N4-guanine 
(N4amG) and glycopeptide (GP) were synthesized for tumor cell proliferation assessment 
and cancer theranostic platform, respectively. N4amG and GP were synthesized and 
radiolabeled with 
99m
Tc and 
68
Ga. The chemical and radiochemical purities as well as 
radiochemical stabilities of radiolabeled N4amG and GP were tested. In vitro stability 
assessment showed both 
99m
Tc-N4amG and 
99m
Tc-GP were stable up to 6 hours, whereas 
68
Ga-GP was stable up to 2 hours. Cell culture studies confirmed radiolabeled N4amG and 
GP could penetrate the cell membrane through nucleoside transporters and amino acid 
transporters, respectively. Up to 40% of intracellular 
99m
Tc-N4amG and 
99m
Tc-GP was 
found within cell nucleus following 2 hours of incubation. Flow cytometry analysis revealed 
99m
Tc-N4amG was a cell cycle S phase-specific agent. There was a significant difference of 
the uptake of
 99m
Tc-GP between pre- and post- paclitaxel-treated cells, which suggests that 
99m
Tc-GP may be useful in chemotherapy treatment monitoring. Moreover, radiolabeled 
viii 
 
N4amG and GP were tested in vivo using tumor-bearing animal models. 
99m
Tc-N4amG 
showed an increase in tumor-to-muscle count density ratios up to 5 at 4 hour imaging. Both 
99m
Tc-labeled agents showed decreased tumor uptake after paclitaxel treatment. 
Immunohistochemistry analysis demonstrated that the uptake of 
99m
Tc-N4amG was 
correlated with Ki-67 expression. Both 
99m
Tc-N4amG and 
99m
Tc-GP could differentiate 
between tumor and inflammation in animal studies. Furthermore, 
68
Ga-GP was compared to 
18
F-FDG in rabbit PET imaging studies. 
68
Ga-GP had lower tumor standardized uptake 
values (SUV), but similar uptake dynamics, and different biodistribution compared with 
18
F-
FDG. Finally, to demonstrate that GP can be a potential drug carrier for cancer theranostics, 
several drugs, including doxorubicin, were selected to be conjugated to GP. Imaging studies 
demonstrated that tumor uptake of GP-drug conjugates was increased as a function of time. 
GP-doxorubicin (GP-DOX) showed a slow-release pattern in in vitro cytotoxicity assay and 
exhibited anti-cancer efficacy with reduced toxicity in in vivo tumor growth delay study. In 
conclusion, both N4amG and GP are transporter-based targeting agents. Radiolabeled 
N4amG can be used for tumor cell proliferation assessment. GP is a potential agent for 
image-guided therapy and drug delivery. 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
 
  
2 
 
1.1. Functional Imaging in Oncology 
There are over 10 million people diagnosed with cancer and over 6 million people 
died from cancer every year worldwide. The adaptation nature and heterogeneity of cancer 
is one of the main reasons that cancer treatment is challenging. To address this challenge, 
functional imaging technologies play important role in personalized cancer medicine [1]. 
Anatomical imaging modalities, such as computed tomography (CT) and magnetic 
resonance imaging (MRI), provide structural detail whereas functional imaging modalities, 
such as positron emission tomography (PET) and single photon emission computed 
tomography (SPECT), provide insight into biological information [2, 3]. 
Functional/biological information from the biodistribution of radiolabeled imaging tracers 
can be obtained by using functional nuclear imaging modalities. The utility of nuclear 
images depend largely on the chemical, pharmacokinetic and pharmacodynamic properties 
of imaging tracers. Hence, molecular imaging research is currently focused on developing 
new radiotracers for both PET and SPECT technologies [4]. 
 
Currently, 2-[fluorine-18] fluoro-2-deoxy-D-glucose, or more informally as 
18
F-
fluorodeoxyglucose (
18
F-FDG) is the most frequently used PET agent in oncology [5]. 
18
F-
FDG was first used as a tumor biomarker in 1980 [6]. 
18
F-FDG is transported into the cell 
through glucose transporter 1 (GLUT 1). It accumulates in cells with high glycolytic 
metabolism. 
18
F-FDG PET provides a noninvasive detection of abnormal activities in 
malignant neoplastic diseases.  
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By far, 
18
F-FDG PET has unmatched clinical utility compared to other functional 
imaging modalities [7]. 
18
F-FDG PET is widely used in many oncology clinical practices in 
diagnosis, treatment planning, monitoring of treatment response, and recurrence follow-up 
[2, 8-14]. It has been reported that 
18
F-FDG PET showed high clinical effectiveness in 
staging or restaging of Hodgkin’s lymphoma, non-small-cell lung carcinoma and staging 
colorectal carcinoma [15]. In addition, hybrid PET and CT equipment improved the 
accuracy of 
18
F-FDG by an average of 10–15% compared with 18F-FDG PET alone [16]. 
Recent studies demonstrated that 
18
F-FDG PET/CT benefits patients with lymphomas, 
melanomas, cancers in head and neck, lung, breast as well as tumors of unknown primary 
origin [14, 16]. 
 
Despite wide clinical applications, 
18
F-FDG PET has certain limitations. Although 
18
F-FDG demonstrates high uptake on malignant tissue, it is not specific for tumor cells. 
Uptake of 
18
F-FDG into highly glycolytic areas including sites of infection and/or 
inflammation may generate false positive results. Normal tissues, including brown fat, 
bladder, muscle, brain and intestines also show high 
18
F-FDG uptake [17]. In addition, in 
those tumors with low glucose uptake, low grade and small size (less than 1 cm), 
18
F-FDG 
shows low sensitivity [5]. Furthermore, in bladder and kidneys, due to high 
18
F-FDG 
excretion, malignant lesions are masked by the high background activity. These drawbacks 
not only illustrate the non-specificity nature of 
18
F-FDG but also limit the application of 
18
F-
FDG in oncology.  An alternative way to avoid these limitations is to target cell proliferation 
using nucleoside analogues. 
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1.2. Imaging Cell Proliferation 
All cancers begin in cells. When a normal cell begins to transform, characters and 
abilities are changing. During this normal to cancer transformation, certain capacities are 
acquired. These capacities include self-sufficiency in growth signals, insensitivity to anti-
growth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis and 
tissue invasive & metastasis [18]. Of these six cancer hallmarks, four of them are cell 
survival- and proliferation-related. Therefore, un-controlled cell proliferation should be 
considered the most important characteristic of cancer cell. 
 
Numerous attempts have been made by researchers to develop specific imaging 
probes for tumor proliferation assessment.  It is known that the uptake of 
18
F-FDG generally 
correlates with cell proliferation in vitro and in vivo [19, 20].  Studies conducted by different 
groups demonstrated that radiolabeled amino acids and their analogues may have similar 
potential in cell proliferation assessment [21, 22]. Without a doubt, sugars (such as 
18
F-
FDG) and amino acids play important roles in cell proliferation; nevertheless, nucleosides 
are the key elements to assess cell proliferation. When a cell proliferates, its DNA must be 
duplicated. Since nucleosides are the required elements in the production of nucleotides, 
which are essential in building DNA, the uptake and consumption of nucleosides must be 
significantly greater in proliferating cells than in resting cells. We may, therefore, 
reasonably conclude that radiolabeled nucleoside analogues are the ideal tumor cell 
proliferative marker candidates.   
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1.3. 
18
F-FLT as a Cell Proliferation Marker 
Design and development of radiolabeled nucleoside analogues which are involved in 
DNA synthesis or incorporated into DNA has been reported by various laboratories [23-27]. 
These probes may be used to assess cell proliferation. For example, 3'-deoxy-3'-
18
F-
fluorothymidine (
18
F-FLT) is a clinically-tested imaging probe. Many studies have been 
performed by various groups to compare the sensitivity and specificity of 
18
F-FDG and 
18
F-
FLT in different tumor types. For example, in glioma,
 18
F-FLT shows greater sensitivity than 
18
F-FDG with higher correlation to proliferation marker, Ki-67 [28]. Treatment response 
assessment is another research hotspot of 
18
F-FLT. The following are few random examples: 
18
F-FLT can be used to define proliferation of tumor treated with cytostatic kinase inhibitor 
[29], predict survival rate of patient with glioma after bevacizumab and irinotecan treatment 
[30], and evaluate dose scheduling [31]. It is worthy to mention that some clinical data 
showed there was a low or even no correlation between 
18
F-FLT tumor uptake and 
proliferation markers [32-35]. The cellular uptake of 
18
F-FLT is mediated by human 
nucleoside transporters (hNTs) [36, 37]. The intracellular 
18
F-FLT will then be 
phosphorylated by a cellular kinase known as thymidine kinase type 1 (TK1) [38]. The 
phosphorylated 
18
F-FLT may participate in the DNA synthesis. 
 
Although there is fairly general agreement that 
18
F-FLT images cellular proliferation 
by mimicking a nucleotide involved in the DNA synthesis process, DNA incorporation of 
18
F-FLT is low [38]. In addition, the chemistry of making 
18
F-FLT is complex [23, 24]; as a 
result, the radiochemical yield of 
18
F-FLT is poor. Furthermore, 
18
F is a cyclotron produced 
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isotope. It can only be obtained from cyclotron, so that the price is high and not everywhere 
available. All of these pitfalls limit the clinical applications of 
18
F-FLT [39].  
 
1.4. Advantages of Using Chelation Chemistry and Generator-produced Isotopes 
To overcome the inconvenience and high cost of 
18
F and the poor radiochemical 
yield and complex synthetic chemistry of 
18
F-FLT, generator-produced isotopes plus 
chelation chemistry can be used to develop a novel radiolabeled nucleoside analogue for 
tumor proliferation assessment. Using chelation chemistry, radioisotopes can be labeled to a 
homing agent through a bifunctional chelator. In other words, a chelator should be 
chemically conjugated to a tumor targeting homing agent with a covalent bond to form a 
single homing agent-chelator conjugate. This non-radioactive cold compound is known as 
drug substance. This cold drug substance can be labeled with radioisotope to form the 
radiolabeled drug product before use for imaging.  
 
Using chelation chemistry, single homing agent-chelator conjugate can be labeled 
with various radioisotopes for different purposes. For example, single drug substance can be 
labeled with 
99m
Tc or 
68
Ga to form two different drug products for SPECT or PET imaging, 
respectively. Another example is an 
188
Re-labeled drug product can be used for internal 
radionuclide therapy. 
99m
Tc is preferred to label imaging probes among other radioisotopes 
because it has favorable low energy (140 keV vs. 511 keV for 
18
F), favorable radiochemical 
half-life (6.01 hours vs. 109.8 minutes for 
18
F), inexpensive isotope cost ($0.21/ mCi vs. 
$30-50/ mCi for 
18
F) and capacity for kit product manufacturing. 
18
F-labeled radiotracers 
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have to be synthesized near the site with a cyclotron and delivered from the manufacturing 
site to the hospital shortly before administration due to the cyclotron-producing property and 
relatively short half-life. The cold drug substance kit product, on the other hand, can be 
stored in the hospital. Once needed, drug product can be produced onsite by adding 
radioisotopes generated from an in-house generator. Many 
99m
Tc-chelating techniques and 
chelators have been established. Cyclam (N4), DTPA, DOTA, sulfur colloid and N2S2 have 
all been reported as being easily labeled with 
99m
Tc with high radiochemical purities and 
yields [40-46]. N4 was chosen for the proposed study due to its higher lipophilicity. The 
relatively higher lipophilicity allows drug product to more easily penetrate the cell 
membrane, leading to greater cellular uptake, decreased kidney accumulation and, as a 
result, reducing renal toxicity. Besides, N4 has a closed-ring structure, which is more rigid 
and stabilizes the radioisotopes.  
 
1.5. Nucleoside Analogues and Lead Compound Selection 
Nucleosides consist of three elements: 1. the heterocyclic based moiety, which is 
usually a purine, pyrimidine or their derivatives. Heterocyclic bases play the key role in the 
recognition process of nucleosides through forming specific hydrogen bonds with other 
nucleosides or proteins. 2. The hydroxymethyl group, which is essential for the 
phosphorylation of the molecule by cellular kinases. The phosphorylated nucleotide will 
then be recognized by cellular proteins to achieve biological activity. 3. The ribose ring, 
which acts like a spacer between the other two elements to keep the heterocyclic base and 
the hydroxymethyl group in the correct orientation and configuration. Plenty of nucleoside 
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analogues have been synthesized and discovered. Many have been approved with promising 
anticancer and antiviral abilities. Among them, some have been successfully developed as 
therapeutic agents in both anticancer and antiviral medicine[47].  
 
Anticancer nucleoside analogues include purine-based nucleoside analogues and 
pyrimidine-based nucleoside analogues. Purine-based anticancer nucleoside analogues, such 
as nelarabine, deoxycoformycin, cladribine, fludarabine, and clofarabine, are mostly 
deoxyadenosine analogues. The only exception is nelarabine, which is a deoxyguanosine 
analogue. All pyrimidine-based nucleoside analogues used currently in clinical anticancer 
treatment are deoxycytidine analogues, including cytarabine, gemcitabine and 
decitabine[48]. The primary mechanism of action of these nucleoside anticancer agents is to 
inhibit DNA replication and DNA repair. DNA polymerase and ribonucleotide reductase 
(RNR) are the two major cellular targets for these agents. Take gemcitabine as an example, 
gemcitabine can penetrate cell membrane through nucleoside transporters (NTs). It is 
phosphorylated by cellular deoxycytidine kinase to form gemcitabine monophosphate. After 
this rate-limiting step, gemcitabine monophosphate can be further phosphorylated to form 
gemcitabine diphosphate and triphosphate, which are two active metabolites. Gemcitabine 
triphosphate inhibits DNA polymerase and it can also be incorporated into DNA to inhibit 
DNA replication and repair. Gemcitabine diphosphate inhibits RNR to decrease cellular 
concentration of dCTP. Cellular uptake of gemcitabine is increased to compensate the low 
concentration of dCTP [49]. Through this self-potentiation process, gemcitabine becomes a 
very potent drug to treat many cancers. 
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Antiviral agents, such as acyclovir, penciclovir and ganciclovir [50] (for HSV 
treatment), and AZT[51] (for HIV treatment), have several features in common. For 
instance, most of them do not have the 3′ hydroxyl groups. Different modifications on the 
base moiety and ribose ring are present. However, it has been found that modifications made 
on ribose ring of nucleoside analogues sometimes causes chemical instability and clinical 
toxicity [25]. To overcoming this drawback, several studies have been directed replacing the 
ribose ring by a different five-membered ring system including carbocycles. Examples of 
this new generation compounds are carbovir [52], lobucavir [53], and lamivudine [47]. 
Among them, lamivudine has been proven for the treatment of both HIV and HBV. Similar 
to anticancer nucleoside analogues, the mechanism of action of antiviral agents is to inhibit 
viral DNA replication. For example, after being transported inside the cell, penciclovir can 
be phosphorylated by either viral thymidine kinase or cellular deoxyguanosine kinase [54]. 
Phosphorylated penciclovir is trapped inside cell and will interrupt viral DNA synthesis to 
stop virus proliferation. 
 
N4amG was designed and synthesized using penciclovir as a lead compound. The 
advantages of choosing penciclovir were:  1. Penciclovir is known as a guanosine analogue 
with high affinity to hNTs. It can be effectively transported into cell through hNTs [54]. In 
other words, penciclovir works as an agonist in human body because it preserves the core 
guanine structure, and guanine is one of the main nucleobases in human body. 2. In addition 
to the core guanine structure, penciclovir has a carbon chain with two hydroxyl groups 
instead of a deoxyribose. The carbon chain makes penciclovir resistant to metabolizing 
enzymes. By this design, penciclovir obtains longer biological half-life and circulation time 
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in human body. 3. The two hydroxyl groups are crucial for pharmacodynamics, especially in 
molecular imaging applications. The hydroxyl groups of penciclovir are phosphorylated by 
cellular deoxyguanosine kinase as soon as penciclovir is transported inside the cell through 
hNTs [54]. Phosphorylated penciclovir is trapped inside cell due to the chemical structure 
change and charging effect. Furthermore, phosphorylated penciclovir can be recognized by 
cellular enzymes, such as DNA polymerases. As a result, it can be incorporated into DNA 
through DNA synthesis process. 4. Penciclovir is favorable for us to use in N4amG 
synthesis because it is a commercially available and clinically used medicine with known 
pharmacokinetics, pharmacodynamics and toxicity [55]. 
 
1.6. Cancer Theranostic Approach 
The term “theranostics” was originally used to describe a treatment platform that has 
a diagnostic test and a targeted therapy based on the results of the diagnostic test [56]. 
Currently, “theranostics” has been used in two distinct definitions. The first one defines 
“theranostics” as a single technology platform contains both therapeutic and diagnostic 
agents. The other is a slightly broader definition.  It defines “theranostics” as a personalized 
therapeutic treatment based on the results of a separate diagnostic technology [57, 58]. The 
following discussion is focused on the narrower definition because from a technology 
platform designer’s point of view, it is more valuable to design and develop a single 
technology platform, which can diagnose, deliver targeted therapy and monitor the response 
to therapy simultaneously.  
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One of the main reasons that cancer treatment still remains challenging is the 
heterogeneity and adaptation nature of cancer. To address the challenge, the integration of 
diagnostic imaging technologies with therapeutic interventions is crucial. Recently, imaging 
technologies have been used increasingly to provide molecular information in anticancer 
drug development [59]. Radiotracers with targeting ability make it possible to assess cancer 
molecularly through imaging. This information can be used to predict treatment response.  
Real-time validation and monitoring of the treatment can be achieved by using imaging 
agents during and after chemotherapeutic drugs are delivered. Tumor volume and tumor 
cellular death can also be imaged to confirm treatment response[1].  
 
Over the past few decades, with developments in imaging technology, materials 
science and cancer biology, a considerable number of theranostic technology platforms have 
been developed to diagnose and treat cancer. These technology platforms, such as polymer-
drug conjugates and complexes, polymeric micelles, liposomes, dendrimers, polymersomes, 
microbubbles, Au/Si/polymer shells and carbon nanotubes, have been well studied and 
established [60, 61]. Thus, part of my research was focused on developing a polymeric drug 
delivery platform using cancer theranostic concept. 
 
1.7. Polymeric Drug Development and Lead Compound Selection 
Among all these technology platforms, according to Siti M. Janib, et.al., “polymer-
drug conjugation is a relatively reliable method to improve pharmacokinetics and increase 
therapeutic index [62]”. Polymer-drug conjugation is prepared through covalent interactions 
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between polymer and drug. The synthetic chemistry pathways used to prepare polymer-drug 
conjugates can be various. It often depends on the chemical properties of both carrier and 
drug. Current developing polymer-drug conjugates used for theranostics include two major 
classes: protein/peptide-based and synthetic polymer-based conjugates. 
 
An example of protein/peptide-based drug conjugation/complexation is albumin-
bound paclitaxel (trade name Abraxane). It uses a high pressure homogenization method to 
form a reversible bond between paclitaxel and albumin [63, 64]. This albumin-bound 
paclitaxel significantly reduces the toxicity compared with conventional paclitaxel through 
decreased off-target activity [63, 65]. Abraxane treatment was approved by the U.S. Food 
and Drug Administration (FDA) in year 2005. Many efforts have been made to conjugate 
doxorubicin (DOX) with synthetic polypeptides to increase solubility and reduce off-target 
toxicity. For instance, DOX was conjugated to a chimeric polypeptide with a 
heterobifunctional linker. The chimeric polypeptide-DOX conjugates are self-assembled to 
form nanoparticle like a micelle. This increases the therapeutic index of DOX through 
increased plasma circulation and cellular internalization [66-69].   
 
In the category of synthetic polymer-based drug conjugates, N-(2-
hydroxypropyl)methacrylamide (HPMA) is one of the most wildly studied carriers because 
of its low immunogenic and non-toxic properties and circulation stability [70, 71]. A variety 
of therapeutic and diagnostic agents have been conjugated with HPMA [72]. For instance, a 
131
I labeled HPMA-DOX conjugate for cancer theranostics purposes is currently in clinical 
trial [73]. In addition, it has been reported that DOX and gemcitabine were both conjugated 
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to HPMA as a single polymer-drugs conjugate [74]. Moreover, using copolymerization 
techniques, multimodal diagnostic and therapeutic drugs have been synthesized and 
evaluated [75, 76].   
 
The objectives of polymer-drug conjugates are three-fold: 1. increase circulation 
time (slow release), 2. decrease toxicity, 3. incorporate targeting moieties to achieve active 
tumor targeting functionalities [77-79]. In order to achieve these objectives and, ultimately, 
to reach high therapeutic index in cancer theranostic technology platform development, it 
would be necessary to design a carrier to target tumor vascular (objective 1 and 2) and 
cellular (objective 3) components. Glycopeptide (GP) technology has then been designed 
and developed.  The structure of GP is a copolymer of chitosan and glutamate peptide. 
These two elements give GP the ability to target tumor vasculature endothelial cells and 
cellular uptake via glutamate transporters.  
 
Chitosan is known as a biocompatible polymer with wound healing, anti-infection, 
anti- inflammatory and tissue adhesive abilities [80-83]. Take wound healing as an example; 
chitosan enhances macrophage activation, anti-inflammatory action, angiogenesis 
stimulation, granulation and scar formation during the healing process. Many 
polysaccharides, including chitosan, chondroitin and hyaluronate have also applied to drug 
delivery[84].  Though chitosan has many advantages in medicine, some significant 
limitations still remain in the treatment of cancer through intracellular delivery of cytotoxic 
drugs.  In order to enhance the cell membrane penetrating ability and the therapeutic index 
of chitosan in cancer treatment, glutamate peptide was conjugated with chitosan. 
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Glutamate is a potent neurotransmitter in the central nervous system and exerts its 
action via glutamate transporters [85]. It is also known that cellular uptake of glutamate 
peptide is specific to glutamate transporter [86].  Chains of 5 or more glutamic acids could 
reduce renal uptake in animal models [87]. In addition, it has been reported that glutamate 
peptide-drug conjugates increased drug efficacy [88]. Moreover, glutamate peptide-
gadolinium complex has been used for MRI applications [89].  Conjugation of GAP with 
chitosan resulting GP would be a novel agent to target tumor vascular and cellular 
component. 
 
GP has multiple amino and carboxylic acid functional groups, which can be 
chemically conjugated with different anti-cancer drugs with carboxylic acid or amino 
groups. The carboxylic acids on the glutamate peptide can be used to label different 
radioisotopes for different purposes. In other words, GP offers opportunities to combine 
passive (tumor vesicular endothelium cell) and active (glutamate transporters) tumor 
targeting, molecular imaging (with radiolabeled GP), controlled drug releasing (with GP-
drug conjugates) and other theranostic advantages, such as monitor and treat disease 
simultaneously. 
 
1.8. Hypothesis and Specific Aims 
The background information provided in this chapter clearly supports the concept 
that nucleoside transporters and amino acid transporters are upregulated in certain tumor 
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cells. Targeting these transporters can be an effective way to assess tumor cell proliferation 
and to deliver anticancer drugs. Collectively, the outlined previously published studies have 
let us to hypothesize that radiolabeled N4amG and GP can actively penetrate the cell 
membrane through transporters. Furthermore, the retention of radiolabeled N4amG and GP 
in tumors will allow specific assessment of tumors. Lastly, I propose that GP-doxorubicin 
conjugates will be more specific and less toxic than doxorubicin in tumor treatment. In an 
attempt to address this hypothesis, the following Specific Aims were formulated: 
 
Specific Aim 1: To synthesize N4amG and GP, and labeled with 
99m
Tc and 
68
Ga. 
 
Specific Aim 2: To investigate radiolabeled N4amG and GP in vitro cellular uptake 
mechanism and pharmacokinetic accumulation. 
 
Specific Aim 3: To evaluate radiolabeled N4amG and GP imaging potential in tumor-
bearing animal models. 
 
Specific Aim 4: Proof of concept by conjugating GP with doxorubicin for targeted 
chemotherapy in animal models. 
 
This dissertation will highlight the results of studies designed to address these 
Specific Aims.  
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CHAPTER 2: MATERIALS AND METHODS 
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2.1. Reagents, Chemicals and Instrumentation 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl and nuclear and cytoplasmic 
extraction reagents (NE-PER) were purchased from Pierce Chemical Company (Rockford, 
IL).  Chitosan (MW. 3,500-5,000, 75% deacetylated) was obtained from Taiwan Hopax 
Chems., Mfg, Company (Kaohsiung, Taiwan). Penciclovir was purchased from LKT 
Laboratories (St. Paul, MN).  All other chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO). 
 
Proton NMR and 
13
C NMR analyses were performed using a Bruker 300 MHz NMR 
spectroscope at the NMR core facility in UT MD Anderson Cancer Center (Houston, TX). 
Mass spectral analyses were conducted at the University of Texas M.D. Anderson Cancer 
Center (Houston, TX, USA). High resolution Mass spectra (multimode as ion source) were 
acquired on an Agilent 6200A accurate Mass time of flight (TOF) system (Santa Clara, CA, 
USA). The elemental analysis data were obtained from Galbraith Laboratories (Knoxville, 
TN).  Radioactive tissue samples were recorded on a Packard gamma counter (Downers 
Grove, IL).  HPLC analyses were performed using Waters C-18 column (Milford, MA). 
Two detectors on HPLC, UV and NaI detectors were used to detect UV absorption and 
radioactivity, respectively. Scintigraphic images were obtained from a gamma camera 
equipped with low-energy, parallel-hole collimator (M-camera, Siemens Medical Systems, 
Inc., Hoffman Estates, IL). MicroPET imaging was obtained from the microPET R4 scanner 
(Concord Microsystem, Knoxville, TN). Silica gel coated instant thin-layer chromatography 
(ITLC) plates were purchased from Gelman Sciences (Ann Arbor, MI). Silica gel coated 
thin-layer chromatography (TLC) plates were purchased from Whatman (Clifton, NJ, USA). 
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Spectra/POR molecular porous membrane with cut-off at 5,000 was obtained from Spectrum 
Medical Industries Inc. (Houston, TX). Immunofluorescence double staining 
deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate-biotin nick end 
labeling (TUNEL) assay kit was purchased from Promega Corporation (Madison, WI). 
Sodium pertechnetate was obtained from a commercial 
99
Mo/
99m
Tc generator 
(Ultratechnekow FMTM, Mallinckrodt Diagnostics, Houston, TX).  
 
2.2. Animals 
All protocols and experiments involving animals (rats, mice and rabbits) were 
approved by the M. D. Anderson Animal Care and Use Committee. The animals were 
housed in The University of Texas M. D. Anderson Cancer Center facility with controlled 
temperature (21-23℃), humidity (50-55%) and light period (on at 0600h, off at 1800h).  
Fischer-344 Rats (150±25g) (Harlan Sprague-Dawley, Indianapolis, IN) were inoculated 
subcutaneously with rat breast adenocarcinoma cells (13762 NF, 10
6
cells/rodent) into the 
right legs. The studies were performed 12 to 15 days after inoculation. Tumor sizes 
approximately 0.8-1 cm were measured.  During that time, the symmetric site at left legs 
was injected with turpentine (0.1 ml) to induce inflammation.  New Zealand white rabbits 
were purchased from UT MD Anderson Cancer Center ( Houston, TX). 
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2.3. Chemistry and Radiochemistry 
2.3.1. Synthesis of N
2
-(p-anisyldiphenylmethyl)-9-[(4-hydroxy)-3-p-anisyldiphenyl-
methoxymethylbutyl]guanine  
Penciclovir (500 mg, 2.43 mmol) was placed in a dry round bottom flask.  
Dimethylformamide (DMF, 20 mL) was added followed by methoxytrityl (1.5 g, 4.85 
mmol), 4-Dimethylaminopyridine (25 mg), and triethylamine (1.75 mL). The reaction 
mixture was under nitrogen gas and was heated at 50℃ for 2 hours with stirring. The 
reaction mixture was cooled to room temperature, diluted with methylene chloride, and 
washed with water. The aqueous phase was extracted with methylene chloride. The 
combined organic phase was dried with anhydrous magnesium sulfate (MgSO4) and 
evaporated to yield oily raw product. Silica gel column chromatography was performed 
using 5% methanol in dichloromethane. 600 mg of the desired product was obtained in 40% 
yield.  
 
2.3.2. Synthesis of N
2
-(p-anisyldiphenylmethyl)-9-[(4-tosyl)-3-p-anisyldiphenylmethoxy-
methylbutyl]guanine  
N
2
-(p-Anisyldiphenylmethyl)-9-[(4-hydroxy)-3-p-anisyl-diphenylmethoxy-
methylbutyl]guanine (600 mg, 0.76 mmol) was dissolved in anhydrous pyridine (10 mL). P-
Toluene sulfonyl chloride (840 mg, 4.3 mmol) was added. The reaction mixture was stirred 
at room temperature for 3 h. The reaction mixture was diluted with methylene chloride, and 
washed with water. The aqueous phase was extracted with methylene chloride. The 
combined organic phase was dried with anhydrous MgSO4 and evaporated to yield the crude 
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product. Silica gel column chromatography was performed using 5% methanol in 
dichloromethane. 250 mg of the desired product was obtained in 34% yield.  
 
2.3.3. Synthesis of 9-[4-amino-3-(hydroxymethyl)butyl]guanine (NH2-Guan, compound I) 
N
2
-(p-anisyldiphenylmethyl)-9-[(4-tosyl)-3-p-
anisyldiphenylmethoxymethylbutyl]guanine (250 mg, 0.38 mmol)was placed in a 
dry round bottom flask. 10 mL DMF and sodium azide (80 mg, 1.2 mmol) was 
added. The reaction mixture was stirred at 100
o
C for 2 hours. The reaction mixture 
was cooled to room temperature, and diluted with dichloromethane followed by 
water washing. The aqueous phase was extracted with dichloromethane. The 
combined organic phase was dried with anhydrous MgSO4 and evaporated to yield 
the crude product.   225 mg of the crude azido compound was obtained. 
1
H NMR 
(CDCl3): δ 8.04 (s, 1H), 7.22-7.45 (m, 20H), 6.86 (d, 4H, J = 9.0 Hz), 6.78 (d, 4H, J 
= 9.0 Hz), 3.79 (s, 3H), 3.76 (s, 3H), 3.55-3.65 (m, 2H), 3.25-3.35 (m, 2H), 1.63-1.73 
(m, 2H), 1.32-1.42 (m, 1H), 1.16 (d, 2H, J = 3.6 Hz). Exact mass calculated for 
C50H46N8O4 [M + H]
 + 
823.3641 found 823.4025. 
 
The crude azido compound (225 mg) was dissolved in anhydrous 
tetrahydrofuran (30 mL) and triphenylphosphine (325 mg, 1.3 mmol) was added.  
The reaction mixture was stirred at room temperature for 16 hours. Hydrochloric 
acid (HCl 5N, 1 mL) was added to the reaction mixture and the whole flask was 
heated under reflux for 5 hours.  The reaction mixture was cooled to room 
temperature and was filtered. The solution was evaporated to dryness. The residue 
was dissolved with water and washed with ethylene chloride. Sodium hydroxide (1N, 
3.5 mL) was added in drop-wise manner to adjust the pH to 7-8. Sephadex-G15 
column chromatography was performed to separate the desired product from 
impurities. After freeze drying (Labconco, Kansas City, MO), 50mg of the desired 
product (compound 1) was obtained in 76% yield. Ninhydrin (2% in methanol) spray 
test demonstrated the presence of amino group.  Proton and 
13
C NMR were 
performed. 
1
H NMR (CDCl3): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61 (m, 
2H), 2.90 (d, 2H, J = 6.0 Hz), 1.72 (m, 2H), 1.43 (m, 1H). FAB MS: 253 [M + H]
+ 
[55]. 
 
2.3.4. Synthesis of Cyclam-(BOC)3 
1,4,8,11-tetraazacyclotetradecane (cyclam) (2 g, 9.98 mmol) was dissolved in 
methylene chloride. Di-tert-butyl dicarbonate (BOC) (5 g, 22.91 mmol) was added to 
the cyclam solution. The resulting solution was stirred at room temperature for 2 
hours. Then, the reaction was stopped and solvent was evaporated by a rotary 
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evaporator. After solvent evaporation, silica gel column chromatography was 
performed using methanol/ methylene chloride system. 4.81 g of the desired product, 
Cyclam-(BOC)3 was obtained in 86% yield. Proton NMR and mass spectrometry 
analyses were conducted. 
1
H NMR (CDCl3): δ 3.08-3.22 (m, 12H), 2.81 (m, 2H), 
2.55 (m, 2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H). Exact mass calculated for 
C25H49N4O6 (M + H)
 +
 501.3574 found 501.3648 [55]. 
 
2.3.5. Synthesis of Cyclam-(BOC)3-EA 
Cyclam-(BOC)3 (6.53 g, 13 mmol) was dissolved in 20 mL of DMF. Ethyl 
bromo acetate (1.34 mL) and potassium carbonate (2.70 g, 19.5 mmol) was added to 
the solution, and the reaction mixture was stirred under nitrogen gas and condenser 
at 80-85℃ for 16 hours. The reaction mixture was filtered. After filtration, the 
filtrate was placed in a rotary evaporator for solvent evaporation. After solvent 
evaporation, extraction was performed twice with chloroform as the organic layer 
and water as aqueous layer. The organic layer was dried with magnesium sulfate and 
filtered. After solvent evaporation, silica gel column chromatography was performed 
using a methanol/ methylene chloride system. 7.21 g of the desired product, Cyclam-
(Boc)3-EA was obtained in 83% yield. Proton NMR and mass spectrometry analyses 
were conducted. 
1
H NMR (CDCl3): δ 4.31 (m, 2H), 3.32 (s, 2H), 3.08-3.22 (m, 12H), 
2.81 (m, 2H), 2.55 (m, 2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H), 1.29 (m, 3H). 
Exact mass calculated for C29H55N4O8 [M + H]
+
 587.3942 found 587.5961 [55]. 
 
2.3.6. Synthesis of Cyclam-(BOC)3-AA 
Cyclam-(BOC)3-EA (4.58 g, 7.8 mmol) was dissolved in 30 mL methanol. 
NaOH (1 N, 15.5ml) was added for hydrolysis. The reaction mixture was stirred at 
room temperature for 2 hours. Methanol solvent was evaporated by a rotary 
evaporator and the remaining aqueous layer was acidified with 1M HCl until pH 
dropped to 6. Extraction was performed twice with ethyl acetate. Ethyl acetate layer 
was dried with magnesium sulfate, filtered and after solvent evaporation, cyclam-
(BOC)3-AA was collected. Proton NMR and mass spectrometry analyses were 
conducted. 
1
H NMR (CDCl3): δ 3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.81 (m, 2H), 2.55 
(m, 2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H). Exact mass calculated for 
C27H51N4O8 [M + H]
 +
 559.3629 found 559.5141 [55]. 
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2.3.7. Synthesis of Cyclam Mono acid-9-[4-amino-3-(hydroxymethyl)butyl]guanine 
Conjugate (N4amG) 
Cyclam-(BOC)3-AA (50 mg, 0.19 mmol) was dissolved in water (5 ml). To 
this colorless solution, sulfo-N-hydroxysuccinimide (sulfo-NHS, 95.5 mg, 0.44 
mmol), 3-ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl (EDC, 84.5 mg, 0.44 
mmol) and compound I (50 mg, 0.20 mmol) were added. The mixture was stirred at 
room temperature for 16 hours. The mixture was frozen dried. 10 mL 50% 
trifluoroacetic acid in methylene chloride was added to the dried residues. The 
reaction mixture was stirred at 50℃ for 30 minutes. Solvent was evaporated by a 
rotary evaporator and the remaining compounds were dissolved in water.  The 
aqueous layer was dialyzed for 24 hours using a Spectra/POR dialysis membrane 
with molecular weight cut-off at 500 Da. (Spectrum Medical Industries Inc., Houston 
TX). After freeze drying, 50mg of the desired product (N4amG) was obtained in 
58% yield.  Mass spectronmetry and HPLC analysis were performed. The purity is 
>97%. 
1
H NMR (D2O): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61 (m, 2H), 
3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.90 (d, 2H, J = 6.0 Hz), 2.81 (m, 2H), 2.55 (m, 
2H), 1.81 (m, 2H), 1.72 (m, 2H), 1.67 (m, 2H), 1.43 (m, 1H). Exact mass calculated 
for C22H41N10O3 [M + H]
 +
 493.3285 found 493.3340 [55]. 
 
2.3.8. Radiolabeling of N4amG with
99m
Tc 
N4amG (5 mg) was dissolved in 0.2 ml distilled water. Subsequently, 0.1 mL 
Tin(II) chloride solution (1 mg in 1 ml of water) and sodium pertechnetate 
(Na
99m
TcO4, 1.0 mCi, Mallinckrodt, Houston, TX) were added sequentially. The 
total volume was adjusted to 1.0 mL by adding adequate amount of distilled water. 
The reaction mixture was kept at room temperature for 10 minutes. The specific 
activity was 5 mg/1 mCi/ml. Radiochemical purity was determined by TLC (ITLC 
SG, Gelman Sciences, Ann Arbor, MI) eluted with saline.  From radio-TLC analysis 
(Bioscan, Washington, DC) and HPLC analysis (Waters, Milford, MA), the 
radiochemical purity was more than 95% [55].  
 
2.3.9. Radiolabeling of N4amG with 
68
Ga 
Radiolabeling of N4amG with 
68
Ga was performed in a standard manner [53]. 
Briefly, N4amG (5 mg) was dissolved in 0.2 ml of water, and 
68
Ga chloride (5 mCi) 
evaporated to dryness and reconstituted in 0.1 ml of sterilized water at room temperature, 
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followed by heating up to 55°C for 10 minutes. Radiochemical purity was determined by 
radio-HPLC. 
 
2.3.10. Synthesis of Glycopeptide (GP) 
To a stirred solution of chitosan (200 mg, MW. 3,500-5,000) in water (4 ml) 
EDC (128.5 mg, 0.67 mmol) was added.  Glutamate peptide sodium salt (200 mg, 
MW. 1,308) was then added.  The mixture was stirred at room temperature for 24 
hours.  The mixture was dialyzed for 48 hours using a Spectra/POR molecular 
porous membrane with cut-off at 5,000 (Spectrum Medical Industries Inc., Houston, 
TX).  After dialysis, the product was filtered and dried using a freeze dryer 
(Labconco, Kansas City, MO).  The GP in the salt form weighed 320 mg [90].   
 
2.3.11. Synthesis of Re-GAP 
Rhenium chemistry has been used to support the binding site or structure of 
99m
Tc [91].  It is known that 
99m
Tc binds to GP through the carboxylic acid moiety of 
glutamate peptide. Thus, glutamate peptide was selected for Re-chemistry instead of 
GP.  Rhenium oxotrichloride (ReOCl3) and triphenylphosphine (41.7 mg, 0.05 
mmol) were added to glutamate peptide (65.5 mg, 0.05 mmol) in a mixture of 
ethanol (3 mL) and DMF (5 mL) solution.  The reaction was refluxed for 30 minutes.  
The solution was filtered and the solvent was evaporated to dryness, yielded 30 mg 
(40%). Proton and 
13
C NMR spectra were performed to determine the structure of 
Re-glutamate peptide [92]. 
 
2.3.12. Synthesis of GP-Doxorubicin (GP-DOX) 
Glutamate peptide sodium salt (500.0 mg) was dissolved in water (6 mL), and the 
solution was cooled to 0°C. Diluted HCl solution (1.0 M) was added drop wise with stirring 
until the pH was between pH 2 to 2.5. During the addition, the glutamate peptide separated 
out of solution. The reaction mixture was warmed to room temperature and stirred for 1 
hour. The solid was filtered and washed with water. The solid was lyophilized. Yield 300.0 
mg. 
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10 mL of anhydrous DMF was added to 200 mg of glutamate peptide and stirred to 
get it dissolved. 35.6 mg of NHS was added followed by the addition of 63.9 mg of 1,3-
dicyclohexylcarbodiimide (DCC). The mixture was stirred for 30 minutes. 180 mg of 
doxorubicin HCl was dissolved in 4mL of DMF and 51.84 µL of triethylamine and it was 
then added to the mixture of GAP, DCC and NHS solution. The final reaction mixture was 
stirred overnight. Next day the solution was filtered and the filtrate was evaporated under 
high vacuum. The residue was dissolved with sodium bicarbonate solution (1 N). The 
solution was filtered with a 45 µm filter and it was then dialyzed with a membrane of 
MWCO 1000 for 24 hours. The dialyzed solution was frozen and lyophilized. Yield after 
lyophilization 230.0 mg.  
 
GAP-DOX 200mg was dissolved in 5 mL water. 19.16mg of EDC was added and 
stirred for 10 minutes then 30 mg of chitosan was added. The mixture was stirred overnight. 
Next day the solution was filtered and the filtrate was dialyzed with 1000MWCO membrane 
for 24 hours. The dialyzed solution was frozen and lyophilized. Yield after lyophilization 
210 mg. Conjugation of doxorubicin was 33.5% (w/w) measured by UV spectroscopy 
method at wavelength 480nm. 
 
2.3.13. Synthesis of GP-Pamidronate (GP-PAM) 
300 mg of poly glutamic acid sodium salt was dissolved in 5 mL of water. 107.6 mg 
of EDC was added and the mixture was stirred for 10 minutes. Meanwhile 110 mg of 
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pamidronic acid was dissolved in water with 1 (N) sodium hydroxide and it was then added 
to the GAP-EDC solution and stirred for overnight. Next day the solution was filtered and 
the filtrate was dialyzed with 1000MWCO membrane for 24 hours. The dialyzed solution 
was frozen and lyophilized. 
 
150 mg of GAP-pamidronic acid was dissolved with water (5mL). 9.8mg of EDC 
was added and stirred for 10 minutes. Thereafter, 15 mg of chitosan was added and the 
mixture was stirred for overnight. Next day the solution was filtered and the filtrate was 
dialyzed with 1000MWCO membrane for 24 hours. The dialyzed solution was frozen and 
lyophilized.  
 
2.3.14. Synthesis of GP-Methotrexate (GP-MTX) 
250 mg of methotrexate was dissolved with 1 (N) sodium hydroxide. 126 mg of EDC 
was added and stirred for 15 minutes. Meanwhile 1.0 gram of chitosan was dissolved in 8 
mL of water. The MTX solution was added to the chitosan solution. The mixture was stirred 
overnight. Next day the solution was filtered and the filtrate was dialyzed with 1000MWCO 
membrane for 24 hours. The dialyzed solution was frozen and lyophilized. Yield after 
lyophilization 690 mg. 
 
97.5 mg of glutamate peptide sodium salt was dissolved in water (4mL). EDC was 
added (156 mg) and stirred for 10 minutes. Meanwhile chitosan-Methotrexate (650 mg) was 
dissolved in 8 mL of water and it was added to the upper solution and the mixture was 
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stirred for overnight. Next day the solution was filtered and the filtrate was dialyzed with 
1000MWCO membrane for 24 hours. The dialyzed solution was frozen and lyophilized. 
Yield after lyophilization 710 mg. Methotrexate conjugation rate was 29.9% (w/w) 
calculated by UV spectroscopy at a wavelength of 370 nm. 
 
2.3.15. Synthesis of GP-folate (GP-FOL) 
242.8 mg of folic acid was dissolved with 1 (N) sodium hydroxide. 122 mg of EDC 
was added and stirred for 15 minutes. Meanwhile 1.0 gram of chitosan (Mw 5849) was 
dissolved in 8 mL of water. The folate solution was added to the chitosan solution. The 
mixture was stirred overnight. Next day the solution was filtered and the filtrate was 
dialyzed with 1000MWCO membrane for 24 hours. The dialyzed solution was frozen and 
lyophilized. Yield after lyophilization 678 mg. 
 
97.5 mg of glutamate peptide sodium salt was dissolved in water (4mL). EDC was 
added (156 mg) and stirred for 10 minutes. Meanwhile chitosan-Folate (650 mg) was 
dissolved in 8 mL of water and it was added to the upper solution and the mixture was 
stirred for overnight. Next day the solution was filtered and the filtrate was dialyzed with 
1000MWCO membrane for 24 hours. The dialyzed solution was frozen and lyophilized. 
Yield after lyophilization 710 mg. folic acid conjugated was 28.7% (w/w) calculated by UV 
spectroscopy at a wavelength of 370 nm. 
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2.3.16. Radiolabeling of GP with 
99m
Tc   
Radiolabeling of GP with 
99m
Tc was performed in a standard manner [93]. 
Briefly, GP (5 mg) was dissolved in 0.2 ml of water and tin chloride (0.1 mg in 0.1 
ml of water) was added at room temperature. Sodium pertechnetate (5 mCi) was 
added.  Radiochemical purity was determined by instant thin-layer chromatography 
(ITLC SG, Gelman Sciences, Ann Arbor, MI) eluted with saline [92].  
 
2.3.17. In vitro Stability Assays of 
99m
Tc-GP  
To demonstrate serum stability of 
99m
Tc-GP, 
99m
Tc-GP was prepared in the 
concentration of 10 mg/1 mCi/ml. GP was prepared in the concentration of 10mg/ml 
and Na
99m
TcO4 (1 mCi)  were added. 0.1 mL of 
99m
Tc-GP was incubated with 0.1 
mL phosphate buffered saline (PBS, pH=7.4) at 0.5-24 hours. In vitro stability of 
99m
Tc-GP was determined by chromatographic analysis as described in the above 
section [92].   
 
2.3.18. Radiolabeling of GP with 
68
Ga   
Radiolabeling of GP with 
68
Ga was performed in a standard manner [94]. 
Briefly, GP (5 mg) was dissolved in 0.2 ml of water, and 
68
Ga chloride (5 mCi) 
evaporated to dryness and reconstituted in 0.1 ml of sterilized water at room 
temperature, followed by heating up to 55
o
C for 10 min. Radiochemical purity was 
determined by ITLC eluted with saline [90].  
 
2.3.19. In vitro Stability Assays of 
68
Ga-GP 
68
Ga-GP was prepared in the concentration of 5 mg/1 mCi/ml.  0.1mL of 
68
Ga-GP was incubated with 0.1 mL phosphate buffered saline (pH=7.4) at 37℃ for 
30-120 minutes. In vitro stability of 
68
Ga-GP was determined by chromatographic 
analysis, as described in section 2.3.17 [90].   
 
2.3.20. Radiolabeling of GP-drug Conjugates with 
99m
Tc   
Radiolabeling of GP-drug conjugates with 
99m
Tc was performed in a standard 
manner[93].  Briefly, GP-drug conjugates (5 mg) were dissolved in 0.2 ml of water and tin 
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chloride (0.1 mg in 0.1 ml of water) was added at room temperature. Sodium pertechnetate 
(5 mCi) was added.  Radiochemical purity was determined by elution with saline. 
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2.4. Pharmacology and Toxicology 
2.4.1. In Vitro Cell Culture Assay of 
99m
Tc-N4amG 
To evaluate whether 
99m
Tc-N4amG can penetrate the cell membrane, an in 
vitro cellular uptake study using 
99m
Tc-N4amG and its chelator control (
99m
Tc-N4) 
was conducted. Cells in a 12-well plate (50,000 cells/ well) were incubated with 
99m
Tc-N4amG or
 99m
Tc-N4 at 37℃ for 30 minutes, 2 hours or 4 hours. Following the 
incubation period, cells were washed with PBS twice and detached with 0.5 mL of 
trypsin solution. After centrifugation, radioactivity was measured by a gamma 
counter. Data was processed and presented in mean ± S.D. [55]. 
 
2.4.2. Cellular Fraction Assay of 
99m
Tc-N4amG 
To determine the distribution pattern of 
99m
Tc-N4amG within the cells, NE–
PER extraction reagents were used stepwise to isolate cytoplasmic and nuclear 
extracts from breast cancer cells. 
99m
Tc-N4amG (0.1 mCi) was prepared in the 
concentration of 0.1 mg/mL. After 20 ml of 
99m
Tc-N4amG (0.02 mg/well, 2 mCi) or 
99m
Tc-N4 (control) was dispensed into each well of a 6-well plate, and cells (50,000 
per well) were incubated at 37℃ for 2 hours. Cells were transferred to a 2 mL 
microcentrifuge tube and isolated by centrifugation at 500 g for 2–3 minutes. 200 μL 
of ice-cold kit reagent (CER I) was added to the cell pellet in other remaining tubes. 
Following 10 minutes of incubation, 11 μL of ice cold CER II was added and 
incubated for an additional 1 minute. The tubes were centrifuged for 5 minutes at 
maximum speed in a microcentrifuge and the supernatant (cytoplasmic extract) 
fractions were transferred to other tubes for counting. Insoluble (pellet) fractions, 
which contain nuclei, were resuspended in 100 μL of ice-cold NER. Following a 
total 40 minutes of incubation, the tubes were re-centrifuged at a maximum speed for 
10 minutes and the supernatant (nuclear extract) fractions were transferred to other 
tubes for counting. Insoluble (pellet) fraction, which contains nuclear material, was 
resuspended in 100 μL of PBS and transferred to other tubes for counting. Samples 
were counted in a gamma counter [55]. 
 
2.4.3. Cellular Blocking Assay of 
99m
Tc-N4amG 
To determine whether cellular uptake of 
99m
Tc-N4amG was via a nuclear transporter, 
the breast tumor cells were incubated with guanine (specific) or glucose at 0.25-1.0 mg/well 
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for 30 minutes, followed by 
99m
Tc-N4amG (4 µCi/well, 0.02 mg/well).  The cells were 
incubated for an additional 20 minutes.   
 
2.4.4. Cell Sorting Assay of 
99m
Tc-N4amG  
To further investigate whether different cell cycle phases have different capacity in 
the uptake of 
99m
Tc-N4amG, cell sorting assay was conducted.  1-2×10
6
 cells were harvested 
and then suspended in 1 mL media. The Hoeches 33342 reagent (prepared in 1 mM stock 
solution) was added to cell suspension to a final concentration of 10 μM.  Cells were 
incubated at 37℃ for 1 hour. After incubation, cells were analyzed and sorted by flow 
cytometry. 
 
Cells were sorted into the various phases of cell cycle (G0/G1, S, and G2/M) 
using fluorescence activated cell sorter (FACS). Sorted cells were suspended in 
15mL test tubes (50,000 cells/ tube). 
99m
Tc-N4amG or
 99m
Tc-N4 was added, and the 
cells were incubated at 37℃ for 60 minutes. Following the incubation period, cells 
were centrifuged and washed with PBS twice. After final centrifugation, 
radioactivity was measured by gamma counter. Data was processed and presented in 
mean ± S.D. [55]. 
 
2.4.5. Biodistribution Studies of 
99m
Tc-N4amG and 
99m
Tc-MIBI in Rats 
Female Fischer 344 rats (150–175 g) were inoculated subcutaneously in the 
right leg with 13762 rat breast cancer cells (10
6
 cells/rat) from the breast cell line. 
Biodistribution studies were performed on day 14 after inoculation. 9 tumor-bearing 
rats were used and divided into three groups, each group representing a time interval 
(0.5, 2, and 4 hr, n=3/time point). 20 Ci of 99mTc-N4amG was injected via a lateral 
tail vein. After administration of the radiotracers, the rats were sacrificed at 0.5, 2 
and 4 hours and the selected tissues were excised, weighed and counted for 
radioactivity with a gamma counter.  The distribution of radiotracer in each organ 
was expressed as percentage of the injected dose per gram of tissue (%ID/g).  
Tumor-to-muscle and tumor-to-blood count ratios were determined from the 
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corresponding %ID/g values. In statistical analysis, percent of injected dose per gram 
of tissue weight (%ID/g) and tumor-to-tissue ratios used in biodistribution studies 
were presented as mean ± S.D. [55].   
 
99m
Tc-methoxyisobutylisonitrile (
99m
Tc-MIBI) was prepared by adding 9.6 mCi of 
99m
Tc-sodium pertechnetate to MIBI kit (INER, Taiwan). Normal saline was added until the 
total volume reached to 9.6 mL (strength: 9.6 mCi/9.6 mL/kit). The vial was incubated in 
boiling water for 15 minutes then cooled-down in room temperature for 15 minutes. 
 
Female Fischer 344 rats (150–175 g) were inoculated subcutaneously in the right leg 
with 13762 rat breast cancer cells (10
6
 cells/rat) from the breast cell line. Biodistribution 
studies were performed on day 14 after inoculation. 12 tumor-bearing rats were used and 
divided into three groups, each group representing a time interval (15 min, 45 min, 2 and 4 
hr, n=3/time point). 20 Ci of 99mTc-MIBI was injected via a lateral tail vein. After 
administration of the radiotracers, the rats were sacrificed at 15, 45 minutes, 2, and 4 hours 
and the selected tissues were excised, weighed and counted for radioactivity with a gamma 
counter.  The distribution of radiotracer in each organ was expressed as percentage of the 
injected dose per gram of tissue (%ID/g).  Tumor-to-muscle and tumor-to-blood count ratios 
were determined from the corresponding %ID/g values. In statistical analysis, percent of 
injected dose per gram of tissue weight (%ID/g) and tumor-to-tissue ratios used in 
biodistribution studies were presented as mean ± S.E.M.    
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2.4.6. Olinda Dosimetry Estimation of 
99m
Tc-N4amG in Rats 
Human radiation dose estimates for 
99m
Tc-N4amG were computed through 
Olinda/EXM software  (Oakridge, TN) [95] from their respective biodistribution data. 
Olinda inputs were calculated using established methods [90, 92]. Briefly, fitted 
residence time functions were plotted and multiplied by the exponential decay 
functions (i.e., half-life) for 
99m
Tc. These functions were then integrated analytically 
to determine the area under the curve (AUC) to yield the residence time of each 
organ. Mass correction factors were used to account for the different ratios of organ 
to total body weights in the rat and in humans, and allowed for the scaling of the rat 
residence times to human residence times. Residence times were then used to 
calculate target organ absorbed radiation doses with S-value tables for a standard 70 
kg male model using the Olinda software package. Each organ dose was computed 
from the sum of self-dose plus the dose it received from each source organ in the 
body or from the remainder of the body. The estimated human radiation absorption 
dose was determined [55]. 
 
2.4.7. Scintigraphic Imaging Studies of 
99m
Tc-N4amG in Rats 
To demonstrate the application of 
99m
Tc-N4amG in breast tumor imaging, 
three breast tumor-bearing rats were administered with 
99m
Tc-N4amG (300 µCi/rat, 
1.0 mg physical amount, iv.)  Scintigraphic images, using a gamma camera equipped 
with low-energy, parallel-hole collimator, were obtained after 1, 2 and 4 hours. The 
standard source used for calibration was 30 µCi of Na
99m
TcO4. Computer outlined 
region of interest measures (counts per pixel) of the tumor and muscle (at the 
symmetric site) were used to determine tumor-to-muscle count density ratios [55]. 
 
2.4.8. Scintigraphic Imaging Studies of 
99m
Tc-N4amG in Rats, Pre- and Post- Treatment 
To demonstrate the application of 
99m
Tc-N4amG in monitoring treatment response, 
three 13762 rat breast tumor-bearing rats were administered with 
99m
Tc-N4amG (300 μCi/rat, 
3 mg physical amount, iv) at pre- and post-paclitaxel treatment (20 mg/kg, iv, single dose) at 
72 hours.  Scintigraphic images, using a gamma camera equipped with low-energy, parallel-
hole collimator, were obtained 0.5 and 1 hour. The standard source used for calibration was 
30 μCi of Na99mTcO4.  Computer outlined region of interest measures (counts per pixel) of 
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the tumor and muscle (at the symmetric site) were used to determine tumor-to-muscle count 
density ratios.  
 
2.4.9. Scintigraphic Imaging Studies of 
99m
Tc-N4amG in Tumor/Inflammation Animal 
Model 
To demonstrate differential diagnosis of 
99m
Tc-N4amG between tumor and 
inflammation, the left legs of 13762 breast tumor-bearing rats (tumor model described in 
section 2.4.5.) were administered with turpentine (0.1 mL, i.m.).  The following day, breast 
tumor-bearing rats were administered with 
99m
Tc-N4amG(300 µCi/rat, 3 mg physical 
amount, iv.) and scintigraphic images, were obtained 2 hours. The standard source used for 
calibration was 30 μCi of Na99mTcO4.  Computer outlined region of interest measures 
(counts per pixel) of the tumor and muscle; tumor and inflammation (at the symmetric site) 
were used to determine count density ratios. 
 
2.4.10. Ki-67 Staining Assay 
 To further investigate the correlation between 
99m
Tc-N4amG tumor uptake and cell 
proliferation marker, Ki-67, tumors were excised from non-treated and paclitaxel-treated 
(20mg/kg, iv. single dose, after 72 hours) rats. The tumor blocks were preserved in 10% 
formalin (approx. 4% formaldehyde) before being sent to the histopathology core facility for 
H&E staining and Ki-67 staining. 
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2.4.11. Kinetic Study of Blood Clearance of 
99m
Tc-N4amG in Rats 
Fischer-344 rats were administered intravenously 2 mCi of 
99m
Tc-N4amG. To 
determine blood clearance and biological half-life of 
99m
Tc-N4amG, 0.1ml blood samples 
were collected from 10 seconds to 20 minutes (14 time points) after injection.  Blood 
samples were weighed and the radioactivities were counted by gamma counter. The 
radioactivity of each sample was calculated as a percentage of the injected dose per gram of 
the blood’s net weight (%ID/g). 
 
2.4.12. In Vitro Cell Culture Assay of 
68
Ga-N4amG 
Cells in a 12-well plate (50,000 cells/ well) were incubated with 
68
Ga-N4amG or 
68
Ga-N4 at 37℃ for 30 minutes, 1 hour, 2 hours or 4 hours. Following the incubation period, 
cells were washed with PBS twice and detached with 0.5 mL of trypsin solution. After 
centrifugation, radioactivity was measured by a gamma counter. Data were processed and 
presented in mean ± S.D. 
 
2.4.13. In Vitro Cell Culture Assays of 
99m
Tc-GP 
13762 cells were plated to a 12-well tissue culture plate that contained 50,000 
cells per each well.  The cells were incubated with 
99m
Tc-GP (2 μCi/well, 0.02 
mg/well) at 37℃ for 0.5-6 hours.  After incubation, cells were washed with ice-cold 
phosphate-buffered saline PBS twice and trypsinized with 0.5 mL of trypsin solution 
to detach tumor cells. Then cells were collected by centrifugation.  The cells were 
weighed and the radioactivity was measured by a gamma counter.  Data were 
expressed in mean ± S.D. percent of cellular uptake per mg of cell weight from three 
measurements [92].  
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2.4.14. Cellular Fraction Assay of 
99m
Tc-GP 
To determine the distribution pattern of 
99m
Tc-GP within the cells, NE-PER 
extraction reagents were used stepwise to isolate cytoplasmic and nuclear extracts 
from 13762 rat breast cancer cells.  
99m
Tc-GP (0.1 mCi) was prepared in the 
concentration of 0.1 mg/mL.  After 20 µl of 
99m
Tc-GP (0.02 mg/well, 2 µCi) or 
Na
99m
TcO4 (control) was dispensed into each well of a 6-well plate, cells 
(50,000/well) were incubated at 37℃ for 2 hours. Cells were transferred to a 2 mL 
microcentrifuge tube and isolated by centrifugation at 500 g for 2-3 minutes. 200 µL 
of ice-cold kit reagent (CER I) was added to the cell pellet in other remaining tubes. 
Following 10 minutes of incubation, 11 µl of ice-cold CER II was added and 
incubated 1 more minute. The tubes were centrifuged for 5 minutes at maximum 
speed in a microcentrifuge (~16,000 x g) and the supernatant (cytoplasmic extract) 
fractions were transferred to other tubes for counting. Insoluble (pellet) fractions, 
which contain nuclei, were resuspended in 100 µL of ice-cold NER. Following a 
total of 40 minutes incubation, the tubes were re-centrifuged at a maximum speed 
(~16,000 x g) for 10 minutes and the supernatant (nuclear extract) fractions were 
transferred to other tubes for counting. The insoluble (pellet) fraction, which contains 
nuclear material, was resuspended in 100 µL of 1 x PBS and transferred to other 
tubes for counting. Samples were counted in a gamma counter [92].     
 
2.4.15. Cellular Uptake Assay of 
99m
Tc-GP, Pre- and Post- Treatment 
To determine whether 
99m
Tc-GP could monitor post-treatment changes, 
13762 rat breast tumor cells (50,000 per each well) were incubated with paclitaxel 
(1-5 µM) for 48 hours.  
99m
Tc-GP was prepared in the concentration of 0.1 mg/0.1 
mCi/mL.  
99m
Tc-GP (2 μCi/well, 0.02 mg/well) was added to the wells and incubated 
for 4 hours before and after paclitaxel treatment.   TUNEL assays were used to 
assess paclitaxel-induced apoptosis in these cells.  TUNEL assays were described in 
our previously published procedure [96]. To determine whether cellular uptake of 
99m
Tc-GP was via a glutamate transporter, the breast tumor cells were incubated with 
glutamate (specific) or aspartate (non-specific) at 0.05-0.3 mg/well, followed by 
99m
Tc-GP (2 μCi/well, 0.02 mg/well).  The cells were incubated for an additional 30 
minutes.  After incubation, cells were washed and trypsinized as described 
previously [92]. 
 
2.4.16. Cellular Blocking Assay of 
99m
Tc-GP 
To determine whether cellular uptake of 
99m
Tc-GP was via a glutamate 
transporter, the breast tumor cells were incubated with glutamate (specific) or 
aspartate at 0.05-0.3 mg/well for 30 minutes, followed by 
99m
Tc-GP (4 µCi/well, 
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0.02 mg/well).  The cells were incubated for additional 20 minutes. After incubation, 
cells were washed and trypsinized as described previously [92]. 
 
 
2.4.17. Biodistribution Studies of 
99m
Tc-GP in Rats 
Female Fischer 344 rats (150-175 g) were inoculated subcutaneously in the 
right leg with 13762 rat breast cancer cells (10
6
 cells/rat) from the breast cell line. 
Biodistribution studies were performed on day 14 after inoculation. A group of 
Female Fischer 344 tumor-bearing rats was injected intravenously with 
99m
Tc-GP (30 
μCi/rat, n=3 rats/time point) through the tail vein. The injected mass was 30 μg per rat.  
At 30 minutes, 3, 5 and 24 hours following administration of the radiotracers, the 
animals were sacrificed and the tumors and selected tissues were excised, weighed, and 
counted for radioactivity with a gamma counter.  The biodistribution of 
99m
Tc-GP in 
each sample was calculated as a percentage of the injected dose per gram of the tissue’s 
wet weight (%ID/g) [92].   
 
2.4.18. MIRD Dosimetry Estimates of 
99m
Tc-GP in Rats 
Rat absorbed doses estimates for 
99m
Tc-GP were computed from their 
respective biodistribution data.  Fitted residence time functions were plotted and 
multiplied by the exponential decay functions (i.e., half-life) for 
99m
Tc.  These 
functions were then integrated analytically to determine the area under the curve 
(AUC) to yield the residence time of each organ.  It was assumed that the injected 
activity distribution was uniformly distributed throughout the body immediately 
following injection. It was further assumed that no excretion occurred after the last 
time point and that the activity distribution remained unchanged after this time point, 
i.e., no biological excretion was assumed past the last time point.  Mass correction 
factors were used to account for the different ratios of organ to total body weights in 
the rat and in humans, and allowed for the scaling of the rat residence times to 
human residence times. For the organs where total organ weight was unavailable, the 
organ weights derived from the Cristy-Eckerman mathematic phantoms [97] for the 
adult male were used to estimate total tissue activity.  Residence times were then 
used to calculate target organ absorbed radiation doses with S-value tables for a 
standard 70 kg male model using the MIRDose 3.1 software package. Each organ 
dose was computed from the sum of the self-dose plus the dose it received from each 
source organ in the body or from the remainder of the body[92, 98]. 
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2.4.19. Scintigraphic Imaging Studies of 
99m
Tc-GP in Rats 
To demonstrate the application of 
99m
Tc-GP in monitoring treatment 
response, three 13762 breast tumor-bearing rats were administered with 
99m
Tc-GP 
(300 μCi/rat, 3 mg physical amount, iv) at pre- and post-paclitaxel treatment (60 
mg/kg, iv., single dose) at 48 hours.  Scintigraphic images, using a gamma camera 
equipped with low-energy, parallel-hole collimator, were obtained 0.5 and 1 hour. 
The standard source used for calibration was 30 μCi of Na99mTcO4.  Computer 
outlined region of interest measures (counts per pixel) of the tumor and muscle (at 
the symmetric site) were used to determine tumor-to-muscle count density ratios [92].  
  
2.4.20. Scintigraphic Imaging Studies of 
99m
Tc-GP in Rats with and without Inflammation 
To demonstrate differential diagnosis of 
99m
Tc-GP between tumor and 
inflammation, the left legs of breast tumor-bearing rats (tumor model described in 
previous Biodistribution Studies) were administered with turpentine (0.1 mL, i.m.).  
The following day, breast tumor-bearing rats were administered with 
99m
Tc-chitosan, 
99m
Tc-glutamate peptide and 
99m
Tc-GP (300 µCi/rat, 3 mg physical amount, iv.) and 
scintigraphic images, were obtained 2 hours. The standard source used for calibration 
was 30 μCi of Na99mTcO4.  Computer outlined region of interest measures (counts 
per pixel) of the tumor and muscle; tumor and inflammation (at the symmetric site) 
were used to determine count density ratios [92]. 
2.4.21. Kinetic study of blood clearance of 
99m
Tc-GP in New Zealand white rabbit 
New Zealand white rabbits were administered intravenously 2 mCi of 
99m
Tc-GP. To 
determine blood clearance and biological half-life of 
99m
Tc-GP, 0.1 ml blood samples were 
collected from 10 seconds to 20 minutes (14 time points) after injection.  Blood samples were 
weighed and the radioactivities were counted by gamma counter. The radioactivity of each 
sample was calculated as a percentage of the injected dose per gram of the blood’s net weight 
(%ID/g). 
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2.4.22. Biodistribution Studies of 
68
Ga-GP in Rats 
Female Fischer 344 rats (150-175 g) were inoculated subcutaneously in the 
right leg with breast cancer cells (10
6
 cells in 0.1mL/rat) from the 13762 cell line. 
Biodistribution studies were performed on day 14 after inoculation. A group of 
Female Fischer 344 tumor-bearing rats was injected intravenously with 
68
Ga-GP or 
18
F-
FDG (30 μCi/rat, n=3 rats/time point) through the tail vein. The injected mass was 30 
μg of 68Ga-GP per rat.  At 30, 60, 120 min following administration of the radiotracers, 
the animals were sacrificed and the tumors and selected tissues were excised, weighed, 
and counted for radioactivity with a gamma.  The biodistribution of 
68
Ga-GP or 
18
F-
FDG in each sample was calculated as a percentage of the injected dose per gram of the 
tissue’s wet weight (%ID/g) [90].  
 
2.4.23. MIRD Dosimetry Estimates of 
68
Ga-GP in Rats 
Rat absorbed doses estimates for 
68
Ga-GP were computed from their 
respective biodistribution data.  Fitted residence time functions were plotted and 
multiplied by the exponential decay functions (i.e., half-life) for 
68
Ga-GP.  These 
functions were then integrated analytically to determine the area under the curve 
(AUC) to yield the residence time of each organ.  It was assumed that the injected 
activity distribution was uniformly distributed throughout the body immediately 
following injection. It was further assumed that no excretion occurred after the last 
time point and that the activity distribution remained unchanged after this time point, 
i.e., no biological excretion was assumed past the last time point.  Mass correction 
factors were used to account for the different ratios of organ to total body weights in 
the rat and in humans, and allowed for the scaling of the rat residence times to 
human residence times.  For the organs where total organ weight was unavailable, 
the organ weights derived from the Cristy-Eckerman mathematic phantoms for the 
adult male were used to estimate total tissue activity. Residence times were then used 
to calculate target organ absorbed radiation doses with S-value tables for a standard 
70 kg male model using the MIRDose Olinda software package (Oakridge, TN). 
Each organ dose was computed from the sum of the self-dose plus the dose it 
received from each source organ in the body or from the remainder of the body. The 
estimated human radiation absorption dose was determined [90].   
 
2.4.24. PET Imaging Studies of 
68
Ga-GP in Rats and Rabbits 
For microPET imaging, the images were acquired on a microPET R4 
scanner, a dedicated 3D small-animal PET (Concorde Microsystems, Knoxville TN). 
A group of  13762 tumor-bearing female Fischer 344 rats was injected intravenously 
with 
68
Ga-GP or 
18
F-FDG (n=3 rats/compound) through the tail veins.  Each animal 
was anesthetized and secured in the microPET. Cradle notches, laser lights and 
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animal felt pen markings were used to insure reproducible animal positioning before 
and after administration of 
68
Ga-GP and 
18
F-FDG. Each animal was injected with 
1.62 μCi/g body weight of 68Ga-GP and 18F-FDG and imaged for 2 hr in a dynamic 
mode. A minimum of ~20 million events were acquired in 120 minutes covering the 
tumor bearing area. The acquired list mode data was then histogramed into frames of 
varying durations using Fourier rebinning. The corresponding images were 
reconstructed into a 128*128*63 (0.72*0.72*1.3mm) matrix using ordered subset 
expectation maximization techniques. All corrections for attenuation, scatter, dead-
time, and randomizations were applied to generate quantifiable images.   Computer 
outlined region of interest measures (counts per pixel) of the tumor and muscle (at 
the symmetric site) were used to determine tumor-to-muscle count density ratios [90].   
 
2.4.25. Kinetic Study of Blood Clearance of 
68
Ga-GP in New Zealand White Rabbit 
New Zealand white rabbits were administered intravenously 2 mCi of 
68
Ga-
GP. To determine blood clearance and biological half-life of 
68
Ga-GP, 0.1ml blood 
samples were collected from 10 seconds to 20 minutes (14 time points) after injection.  
Blood samples were weighed and the radioactivities were counted by a gamma counter. 
The radioactivity of each sample was calculated as a percentage of the injected dose per 
gram of the blood’s net weight (%ID/g) [90]. 
 
2.4.26. Animal Acute Toxicity Studies of GP 
Three species (rat, mouse and rabbit) were used to test the acute toxicity of GP. 
Rat 
48 Fischer-344 rats (Male (24) and Female (24), 195+ 5g) were used. After a 2-day 
acclimatization period, rats were placed in cages (3 rats per cage). Following two control 
days, rats were administered an intravenous injection (tail vein) of saline and GP (100, 200 
and 400 mg/kg) and food intake and body weight were measured daily. The GP was 
formulated in saline (0.9%) solution. The injection volume/mouse was 0.3-1.0 ml. Control 
groups were administered saline only. Blood chemistry and histopathology (liver, kidney 
and heart) were performed on day 3 and 14 following single injection of GP or saline.   
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Mouse 
To ascertain acute toxicity findings in different species, Swiss Webster mice (male 
and female, n=5/gender) were administered GP (1.0 g/kg) and the mice were observed for 
14 days.  The body weight was obtained every other day.   
Rabbit 
Acute single-dose toxicity studies were also conducted in a rabbit model.  The 
rabbits (3 kg body weight) were administered saline or GP at 200 mg/kg, iv. (n=2 per 
compound).  Blood chemistry was performed at 14 days post-administration.   
 
2.4.27. Scintigraphic Imaging Studies of 
99m
Tc-GP-drug Conjugates 
To demonstrate the application of GP chemistry in tumor targeting, two groups of 
female Fischer 344 tumor-bearing (right leg) rats were administered with 300 μCi of 99mTc-
labeled compounds (3 mg).  The standard source used for calibration was 30 μCi of 
Na
99m
TcO4.  Computer outlined region of interest measures (counts per pixel) of the tumor 
and muscle (at the symmetric site) were used to determine tumor-to-muscle count density 
ratios.  In the first group, the tumor-bearing rats were administered with chitosan (Chi, 
control), GP, GP-methotrexate (GP-MTX), GP-folate (GP-FOL), GP-doxorubicin (GP-
DOX) and GP-pamidronate (GP-PAM).   
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2.4.28. In Vitro Cellular Toxicity Assay (MTT assay) of GP-DOX 
To determine the cytotoxicity of GP-DOX, MDA-MB-231 cells (7,500/well) were 
incubated in a 96-well plate at 37℃overnight. Cells were then treated with GP, DOX or GP-
DOX at different concentrations (1-500 µg/mL) for 24 to 48 hours. After incubation, 20 µL 
of MTT stock solution (5 mg/mL) was added to each well followed by incubation at 37℃for 
4 hours. After carefully removing the culture media, 100 µL of DMSO was added to each 
well. The 96-well plate was covered by tinfoil and shook on an orbital shaker for 15 
minutes. Finally, the absorbances were read at 590 nm with a ELISA reader to determine the 
cell viability [99]. 
 
2.4.29. In Vitro Cellular Fraction Assay of GP-DOX 
To determine the distribution pattern of 
99m
Tc-GP-DOX within the cells, NE-PER 
extraction reagents were used for stepwise to isolate cytoplasmic and nuclear extracts from 
breast cancer cells. The detailed procedure was described in a previous section (2.4.2). 
Briefly, 
99m
Tc-GP-DOX (0.1 mCi) was prepared in the concentration of 0.1 mg/mL.  After 
20 µl of 
99m
Tc-GP-DOX (0.02 mg/well, 2 µCi) or Na
99m
TcO4 (control) dispensed into each 
well of a 6-well plate and 13762 cells (50,000/well) were incubated at 37℃ for 2 hours. 
After incubation, cellular fractions were obtained using NE-PER extraction reagents. 
Cellular fraction samples were counted in a gamma counter.     
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2.4.30. Scintigraphic Imaging Studies of 
99m
Tc-GP-DOX 
To demonstrate the retention of 
99m
Tc-GP-DOX in breast tumor cells, 13762 breast 
tumor-bearing rats were administered with 
99m
Tc-GP-DOX (300 µCi/rat, 1.0 mg physical 
amount, iv.)  Scintigraphic images, using a gamma camera equipped with low-energy, 
parallel-hole collimator, were obtained after 2 and 24 hr. The standard source used for 
calibration was 30 µCi of Na
99m
TcO4. Computer outlined region of interest measures 
(counts per pixel) of the tumor and muscle (at the symmetric site) were used to determine 
tumor-to-muscle count density ratios. 
 
2.4.31. In Vivo Anti-tumor Ability Studies of GP-DOX 
 MDA-MB-231 cells (3×10
6
 cells/0.1 mL PBS) were inoculated subcutaneously on 
the back of nude mice. Tumor size was measured three times a week once tumors reached 
around 30mm
3
. Once tumors reached 250 mm
3
, different doses of DOX (10 and 20mg/kg), 
GP-DOX (100-600mg/kg) and saline (control) were injected intravenously through tail vain. 
Tumor sizes were measured carefully until the animal died. Tumor growth delay curves and 
survival curves were generated from measured data. 
 
 Absolute tumor growth delay in different treatment groups was calculated by using 
the time (in days) required for the tumor to grow from 70 to 500 mm
3
 minus the time 
required for control group tumors to reach the same size (70 to 500 mm
3
).This data was used 
to evaluate the efficacy for each agent.  
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CHAPTER 3: RADIOLABELED N4amG AS A NUCLEOSIDE TRANSPORTER 
TARGETING AGENT FOR TUMOR CELL PROLIFERATION ASSESSMENT 
 
Portions of this work have been published in Tsao N, Chanda M, Yu DF, Kurihara H, Zhang 
YH, Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: Synthesis Biodistribution and Imaging in 
Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113. 
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3.1. Rationale and Study Design 
As mentioned in Chapter 1, modern imaging technologies provide non-invasive, high 
resolution functional imaging to assess cancer cell proliferation. With proper radiotracers, 
both PET and SPECT can be used to evaluate tumor growth potential, determine the degree 
of malignancy, and even predict and monitor the treatment responses.  
 
18
F-FDG targets glycolysis pathway. Highly glycolytic areas may generate false 
positive results in 
18
F-FDG-PET imaging. Targeting cell proliferation may overcome these 
false positive results because uncontrolled cell proliferation is a distinguishing characteristic 
of tumor. Clinical data also supports that nucleoside-based imaging agents will have higher 
tumor specificity than 
18
F-FDG in many cancers [100, 101]. Therefore, radiolabeled N4amG 
is anticipated to show high specificity in detecting tumors. 
 
Each synthesized chemical was carefully purified and characterized using NMR, 
mass spectrum and HPLC. The radiochemical purity of each radiolabeled compounds were 
tested by radio-HPLC and radio-TLC.  
 
To investigate the pharmacology of radiolabeled N4amG, a series of in vitro and in 
vivo studies using 13762 cells were conducted. 13762 rat breast adenocarcinoma cells were 
used in both in vitro cellular uptake studies and in vivo animal studies because 13762 cells 
were well characterized and established in our laboratory.  
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An in vitro cellular uptake study using radiolabeled N4amG and its chelator control 
was conducted to test the cell penetrating ability of radiolabeled N4amG. Cell sorting 
assays, cellular fraction studies and in vitro blocking studies using guanine as a competitive 
blocker were conducted to investigate the uptake mechanism. 
 
A biodistribution study using 13762 tumor-bearing rats was used to evaluate the 
exact tumor and organ uptake of both radiolabeled 
99m
Tc-N4amG and 
99m
Tc-N4 ex vivo. The 
distribution of radiotracer in each organ was expressed as percentage of the injected dose per 
gram of tissue (%ID/g).  Tumor-to-normal tissue count ratios were determined from the 
corresponding %ID/g values. The result of the rat biodistribution study was further used to 
estimate human radiation absorption dose by using the Olinda software [95], which is a FDA 
approved software for human dose estimation.  
 
An in vivo imaging study was conducted to investigate the imaging potential of using 
99m
Tc-N4amG as a tumor proliferation marker. Tumor-to-muscle count density ratios were 
determined by dividing ROI measures (in counts per pixel) of tumor by ROI measures of the 
symmetric normal muscle site.  The ratios were used to evaluate the potential of 
99m
Tc-
N4amG in tumor uptake. In addition, 
99m
Tc-N4amG was used to image tumor-bearing rats 
before and after paclitaxel treatment. This study was used to evaluate the treatment 
monitoring ability of 
99m
Tc-N4amG. Furthermore, inflammation and tumor dual-bearing rats 
were used to investigate the tumor specificity of 
99m
Tc-N4amG. To determine the important 
pharmacological factor, biological half-life of 
99m
Tc-N4amG in blood, a blood clearance 
study was also performed. 
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To further investigate the correlation between 
99m
Tc-N4amG tumor uptake and tumor 
cell proliferation, immunohistochemistry analysis using Ki-67 as a cellular proliferation 
marker in tumor-bearing rats was conducted. Adequate tumor samples were surgically 
removed. Biopsy tumor samples were then formalin-fixed, paraffin-embedded and cut into 
4μm sections in a standard manner. Tumor sections were immunohistochemically stained by 
anti-Ki67 mouse monoclonal antibody.  
 
For the statistical analysis, the percent of injected dose per gram of tissue weight 
(%ID/g) and tumor-to-tissue ratios used in ex vivo biodistribution studies were presented as 
mean ± S.D.   The uptakes of 
99m
Tc-N4amG and control tracer were compared using a 
Student’s t-test.  Differences were considered to be statistically significant for a two-tailed 
p<0.05.   
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3.2. Results 
3.2.1. Chemistry and Radiochemistry 
3.2.1.1. Synthesis of 9-[4-amino-3-(hydroxymethyl)butyl]guanine (NH2-Guan, compound I) 
NH2-Guan was synthesized through a 4-step reaction route. Briefly, the amino 
functional group and one of the hydroxyl functional groups of penciclovir were selectively 
protected by methoxytrityl protection group. The protected penciclovir was reacted with p-
toluene sulfonyl chloride to convert the unprotected hydroxyl group to a tosyl group. The 
tosylated penciclovir was reacted with sodium azide to form the azido penciclovir. The 
crude azido penciclovir was then dissolved in anhydrous tetrahydrofuran and 
triphenylphosphine was added to reduce azido to amino penciclovir.  Finally, hydrochloric 
acid was added to de-protect all the functional groups.  After Sephadex-G15 column 
purification, the desired product (NH2-Guan) was obtained. Ninhydrin (2% in methanol) 
spray test demonstrated the presence of amino group.  Proton and 
13
C NMR were performed. 
1
H NMR (CDCl3): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61 (m, 2H), 2.90 (d, 2H, J 
= 6.0 Hz), 1.72 (m, 2H), 1.43 (m, 1H). FAB MS: 253 [M + H] 
+
 (Figures 1-4). 
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Figure 1. HPLC analysis of NH2-Guan.   
 
The retention time of NH2-Guan was 10.12 minutes.  
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Figure 2. Mass spectrum analysis of NH2-Guan. 
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Figure 3. Proton NMR analysis of NH2-Guan
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Figure 4. 
13
C NMR analysis of NH2-Guan.
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3.2.1.2. Synthesis of Cyclam-(BOC)3-AA 
Cyclam-(BOC)3-AA was synthesized through a 3-step reaction route. Briefly, 
1,4,8,11-tetraazacyclotetradecane (cyclam) was dissolved in methylene chloride. Three of its 
four amino groups were selectively protected with boc protection groups to form cyclam-
(BOC)3. Cyclam-(BOC)3 was dissolved in DMF and reacted with ethyl bromo acetate  to 
form cyclam-(BOC)3-EA. Cyclam-(BOC)3-EA was then de-protected under base conditions 
to obtain cyclam-(BOC)3-AA. Proton NMR and mass spectrometry analyses were 
conducted. 
1
H NMR (CDCl3): δ 3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.81 (m, 2H), 2.55 (m, 
2H), 1.81 (m, 2H), 1.67 (m, 2H), 1.38 (m, 27H). Exact mass calculated for C27H51N4O8 [M + 
H]
 +
 559.3629 found 559.5141 (Figures 5 and 6). 
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Figure 5. Proton NMR analysis of cyclam-(BOC)3-AA.
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Figure 6. Mass spectrum analysis of cyclam-(BOC)3-AA.
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3.2.1.3. Synthesis of Cyclam Mono acid-9-[4-amino-3-(hydroxymethyl)butyl]guanine 
Conjugate (N4amG) 
Cyclam-(BOC)3-AA was reacted with NH2-Guan under water conditions (Figure 7). 
At the presence of sulfo-NHS and EDC, an amide linkage was formed between the 
carboxylic acid of cyclam-(BOC)3-AA and the amino group of NH2-Guan. After de-boc and 
dialysis, the desired product (N4amG) was obtained.  Mass spectronmetry and HPLC 
analysis were performed. 
1
H NMR (D2O): δ 7.60 (s, 1H), 3.98 (t, 2H, J = 7.2 Hz), 3.46-3.61 
(m, 2H), 3.32 (s, 2H), 3.08-3.22 (m, 12H), 2.90 (d, 2H, J = 6.0 Hz), 2.81 (m, 2H), 2.55 (m, 
2H), 1.81 (m, 2H), 1.72 (m, 2H), 1.67 (m, 2H), 1.43 (m, 1H). Exact mass calculated for 
C22H41N10O3 (N4amG) [M + H]
 +
 was 493.3358 found 493.3340 (Figure 8). HPLC 
spectra showed that the purity of N4amG was greater than 95% (Figure 9). After NMR 
confirmation (Figure 10), the impurity (<5%, retention time: 14.915 min) was protected 
precursor.  
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Figure 7. Schematic of N4amG synthesis. 
 
Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: 
Synthesis Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.  
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Figure 8. Mass spectrum analysis of N4amG.  
 
Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: 
Synthesis Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.  
  
58 
 
 
Figure 9. HPLC analysis of N4amG.  
 
The spectra showed that the purity of N4amG was greater than 97%. Reprinted with permission from Tsao N, Chanda M, Yu DF, 
Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: Synthesis Biodistribution and Imaging in Breast Tumor-bearing 
Rodents. Applied Radiation and Isotopes 72: 105-113.   
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Figure 10. Proton NMR analysis of N4amG.   
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3.2.1.8. Radiolabeling of N4amG with
99m
Tc 
N4amG (5 mg) was dissolved in 0.2 ml distilled water. Subsequently, 0.1 mL Tin 
(II) chloride solution (1 mg in 1 ml of water) and sodium pertechnetate (Na
99m
TcO4, 1.0 
mCi, Mallinckrodt, Houston, TX) were added sequentially. The total volume was adjusted to 
1.0 mL by adding adequate amount of distilled water. The reaction mixture was kept at room 
temperature for 10 minutes. The specific activity was 5 mg/1 mCi/ml. Radiochemical purity 
was determined by ITLC eluted with saline.  From radio-TLC analysis (Bioscan, 
Washington, DC) and HPLC analysis (Waters, Milford, MA), the radiochemical purity was 
more than 95% (Figure 11).  
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Figure 11. Radio-HPLC analysis of 
99m
Tc-N4amG.  
 
The spectra showed that the radiochemical purity of 
99m
Tc-N4amG was greater than 95%. 
Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH, 
Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: Synthesis Biodistribution and Imaging in Breast 
Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.  
 
 
  
62 
 
3.2.1.9. Synthesis of 9-[4-bromo-3-(hydroxymethyl) butyl]guanine (Bromo-Guan) 
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ, 170.25 mg, 0.75 mmol), 
triphenylphosphine (196.72 mg, 0.75 mmol) and tetrabutylammonium bromide (241.79 mg, 
0.75 mmol) was dissolved in 20mL anhydrous dichloromethane. The reaction mixture was 
stirred for 5 minutes at room temperature and then tritylated penciclovir (0.5 g, 0.625 mmol) 
was added and stirred for 3 hours. The solvent was rotary evaporated and the crude product 
was column purified with 1-5% methanol in dichloromethane as mobile phase.  Exact mass 
calculated was 316.03 found 316.4 (Figures12-15). 
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Figure 12. Mass spectrum analysis of Bromo-Guan.  
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Figure 13. HPLC analysis of Bromo-Guan.  
 
The retention time of Bromo-Guan was 5.69 minutes whereas the retention time of 
penciclovir was 4.88 min. 
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Figure 14. Proton NMR analysis of Bromo-Guan.  
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Figure 15. 
13
C NMR analysis of Bromo-Guan.   
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3.2.1.10. Synthesis of N2-(p-anisyldiphenylmethyl)-9-[(4-iodo)-3-p-
anisyldiphenylmethoxymethylbutyl]guanine (Iodo-Guan-dt) 
N2-(p-anisyldiphenylmethyl)-9-[(4-tosyl)-3-p-
anisyldiphenylmethoxymethylbutyl]guanine (190 mg, 0.2 mmol) was placed in a dry round 
bottom flask. 40 mL of acetone and potassium iodine (996 mg, 16.0 mmol) was added. The 
reaction mixture was stirred at 55℃ for 16 hours. The reaction mixture was cooled to room 
temperature, and was evaporated by a rotary evaporator. The crude product was re-dissolved 
in 40 mL dichloromethane and water washed.  The aqueous phase was extracted with 
dichloromethane. The combined organic phase was dried with anhydrous MgSO4 and 
evaporated to yield the crude product.   129 mg of the crude iodo compound was obtained. 
Exact mass calculated for C50H46IN5O4 [M + H]
 +
 908.2594 found 908.2670 (Figure 16). 
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Figure 16. Mass spectrum analysis of Iodo-Guan-dt. 
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3.2.1.11. Synthesis of 1,5,8,12-tetraazabicyclohexadecane-13, 14-dione (N4-Oxalate)  
1,4,8,11-tetraazacyclotetradecane (cyclam) (15.00 g; 74.88 mmol) was dissolved in 
150 mL of ethanol anhydrous ethanol, and diethyl oxalate (10.94 g; 74.88 mmol) was added. 
The reaction mixture was refluxed 18 hours at 75℃. The solvent was rotary evaporated and 
the crude product was re-crystallized in acetone to yield white crystals. Yield: 13.64 g 
(17.31 mmol; 72%). 
1
H NMR (CDCl3) δ=4.35 (m, 2H), 3.75 (m, 2H), 3.40 (m, 2H), 2.77 (m, 
2H), 2.68 (m, 2H), 2.54 (m, 2H), 2.43 (m, 4H), 1.75 (m, 2H), 1.24 (m, 2H). 
13C NMR δ= 
158.55, 49.92, 49.38, 47.73, 44.13, 25.42 (Figure 17). MS: m/z = 255.33[M] 
+
. 
 
  
70 
 
 
 
Figure 17. 
13
C NMR analysis of N4-Oxalate.  
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3.2.1.12. Attempt to Synthesize N4-Guan 
Many efforts have been made to synthesize N4-Guan from Bromo-Guan or Iodo-
Guan with N4 or N4-Oxalate (Table 1). After TLC, NMR and mass spectrum analysis, none 
of these attempts had successfully obtained N4-Guan. 
 
 
 
Table 1. Different reaction conditions used to synthesize N4-Guan 
Starting 
Materials
(Br-G-dt/Br-G +)
Solvent Base Conditions
N4-Oxa DMF Triethylamine 90°C, 16hr
N4 DMF - 85°C, 16hr
N4-Oxa DMF - 1. 75°C, 16hr   
2. 65°C, 48hr
N4 Ethanol, H2O 1. K2CO3 70°C, ~48hr 
pH=9-10
2. NaOH
N4-Oxa        Acetonitrile K2CO3 65°C, 48hr
N4
NH HN
NH HN
N HN
N HN
O
O
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3.2.1.13. Attempt to Synthesize EC-Guan 
Only 5.2mg of EC-Guan has been gained from 6 gram of penciclovir. The yield was 
<1%. Proton NMR was conducted to confirm the structure (Figure 18). 
 
1.0 mg of EC-Guan was used to label with 
99m
Tc-NaTcO4 in a standard manner. 
Radio-HPLC was used to analyze the radiochemical purity.  The retention time of 
99m
Tc-EC-
Guan (5.3 minutes) was different and longer than 
99m
Tc-EC (4.6 minutes) (Figure 19). The 
finding indicated that EC-Guan was successfully synthesized and had high chelating ability. 
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Figure 18. Proton NMR analysis of EC-Guan.
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Figure 19. Radio-HPLC analysis of 
99m
Tc-EC and 
99m
Tc-EC-Guan.  
 
The longer retention time of 
99m
Tc-EC-Guan (5.3 minutes) indicated the higher hydrophobic 
properties than 
99m
Tc-EC. 
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3.2.2. Pharmacology and Toxicology 
3.2.2.1. In vitro cellular uptake assay 
To evaluate whether 
99m
Tc-N4amG can penetrate the cell membrane, an in vitro 
cellular uptake study using 
99m
Tc-N4amG and its chelator control (
99m
Tc-N4) was 
conducted. High cellular uptake (up to 17%ID at 4 hour) of 
99m
Tc-N4amG in breast tumor 
cells was observed in a cellular uptake study (Figure 20). The accumulation increased with 
increase in incubation time suggesting 
99m
Tc-N4amG has tumor targeting potential.  
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Figure 20. In vitro cellular uptake of 
99m
Tc-N4amG.  
 
13762 rat breast tumor cells (50,000 per each well) were incubated with 2 µCi of 
99m
Tc-
N4amG at 37℃ at 0.5-4 hours. There was a gradually increased uptake of 99mTc-N4amG in 
mammary tumor cells. Data are expressed in mean ± S.D. percent of incubation dose from 
three measurements. Reprinted with permission from Tsao N, Chanda M, Yu DF, Kurihara 
H, Zhang YH, Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: Synthesis Biodistribution and 
Imaging in Breast Tumor-bearing Rodents. Applied Radiation and Isotopes 72: 105-113.  
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3.2.2.2. In Vitro Cellular Fraction Assay 
To determine the distribution pattern of 
99m
Tc-N4amG within the cells, NE–PER 
extraction reagents were used stepwise to isolate cytoplasmic and nuclear extracts from 
13762 rat breast cancer cells. Nucleus fraction had 40% uptake of 
99m
Tc-N4amG whereas 
cytosolic fraction had 60%. Both nucleus and cytosolic fractions in 
99m
Tc-N4amG were 
higher than 
99m
Tc-N4 (Figure 21). The data indicated that 
99m
Tc-N4amG, but not 
99m
Tc-N4, 
could penetrate the cell membrane, and about 40% of 
99m
Tc-N4amG was accumulated in the 
cell nucleus.  
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Figure 21. In vitro cellular fractions of 
99m
Tc-N4amG.  
 
After 2 ml of radioactive media containing 2 µCi (0.074 MBq) of 
99m
Tc-N4amG (0.02 
mg/well) or 
99m
Tc-N4 (control) was dispensed into each well of a 6-well plate, cellular 
fractions were isolated by using an NE-PER extraction kit. Nucleus fraction had 40% uptake 
of 
99m
Tc-N4amG, whereas cytosolic fraction had 60%. Both nucleus and cytosolic fractions 
in 
99m
Tc-N4amG were higher than 
99m
Tc-N4. Data were expressed in mean ± S.D. percent of 
incubation dose from three measurements. Reprinted with permission from Tsao N, Chanda 
M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: Synthesis 
Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and 
Isotopes 72: 105-113.  
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3.2.2.3. In Vitro Cellular Blocking Assay 
To determine whether cellular uptake of 
99m
Tc-N4amG was via nucleoside 
transporter, guanine was used as competitive blocker to perform the cellular blocking assay. 
There was decreased uptake in cells treated with guanine but not with glucose (Figure 22).  
The results suggested that cellular uptake of 
99m
Tc-N4amG was via nucleoside transporters. 
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Figure 22. In vitro cellular blocking assay of 
99m
Tc-N4amG.  
 
13762 rat breast tumor cells were incubated with guanine (specific) or glucose at 0.25-1.0 
mg/well for 30 minutes, followed by 
99m
Tc-N4amG (4 µCi/well, 0.02 mg/well).  The cells 
were incubated for additional 20 minutes.   Data were expressed in mean ± S.D. percent of 
incubation dose from three measurements.  
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3.2.2.4. In Vitro Cellular Sorting Assay 
To further investigate whether different cell cycle phases have different capacity in 
the uptake of 
99m
Tc-N4amG, a cell sorting assay was conducted.  Cells in S phase showed 
highest uptake of 
99m
Tc-N4amG followed by G2/M phase (Figure 23). Compared to 
chelator-only control (
99m
Tc-N4), 
99m
Tc-N4-Guan showed greater uptake in each cell cycle 
phases. These data suggested 
99m
Tc-N4amG was a cell cycle S phase-specific radiotracer.   
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Figure 23. In vitro cell sorting assay of 
99m
Tc-N4amG.  
 
Cells were sorted into the various phases of cell cycle (G0/G1, S, and G2/M) using 
fluorescence activated cell sorter. Sorted cells were suspended in 15mL test tubes (50,000 
cells/ tube). 
99m
Tc-N4-Guan or
 99m
Tc-N4 was added, and the cells were incubated at 37 ℃ 
for 60 min. Following the incubation period, cells were centrifuged and washed with PBS 
twice. After final centrifugation, radioactivity was measured by gamma counter. Data were 
processed and presented as mean ± S.D. Reprinted with permission from Tsao N, Chanda 
M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 
99m
Tc-N4amG: Synthesis 
Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied Radiation and 
Isotopes 72: 105-113.  
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3.2.2.5. Biodistribution Studies 
In biodistribution studies, there was an increased uptake in tumor-to-blood and 
tumor-to-muscle ratios in breast tumor-bearing rats. The optimum tumor uptake and tumor-
to-muscle ratios were obtained 2–4 hours post-administrations. There was no increased 
uptake in thyroid and stomach suggesting in vivo stability of 
99m
Tc-N4amG (Tables 2 and 3). 
99m
Tc-N4amG was excreted through liver and kidneys. Relatively high uptake in bone and 
spleen was observed, suggesting 
99m
Tc-N4amG could target organs with high proliferation 
properties. 
 
99m
Tc-MIBI biodistribution using 13762 tumor-bearing rats (Table 4) showed similar 
main organs uptake with the published data (Table 5) [102]. 
99m
Tc-MIBI washed out from 
blood quickly and accumulated in heart. The heart-to-blood count ratios reached 42.02 at 30 
minutes after injection.  Compared to 
99m
Tc-MIBI, 
99m
Tc-N4amG showed longer blood 
retention and higher liver, tumor, spleen and bone uptake. 
  
84 
 
Table 2. Biodistribution of 
99
Tc-N4 in breast tumor-bearing rats 
______________________________________________________________________________ 
% of injected dose per gram of tissue weight (n=3/time, interval, iv) 
  0.5 HR 2 HR 4 HR 
BLOOD 0.23 ±0.009 0.04 ±0.002 0.02 ±0.002 
HEART 0.07 ±0.005 0.01 ±0.001 0.01 ±0.000 
LUNG 0.20 ±0.011 0.05 ±0.002 0.03 ±0.001 
THYROID 0.25 ±0.011 0.03 ±0.002 0.02 ±0.001 
PANCREAS 0.07 ±0.007 0.02 ±0.002 0.02 ±0.001 
LIVER 2.98 ±0.083 1.14 ±0.018 0.79 ±0.026 
SPLEEN 0.35 ±0.026 0.37 ±0.007 0.39 ±0.020 
KIDNEY 2.56 ±0.101 1.11 ±0.045 0.65 ±0.028 
STOMACH 0.12 ±0.005 0.02 ±0.001 0.01 ±0.000 
INTESTINE 0.25 ±0.004 0.39 ±0.048 0.14 ±0.003 
UTERUS 0.16 ±0.014 0.02 ±0.001 0.01 ±0.001 
TUMOR 0.09 ±0.004 0.03 ±0.003 0.02 ±0.001 
MUSCLE 0.05 ±0.002 0.01 ±0.000 0.01 ±0.000 
BONE 0.07 ±0.001 0.02 ±0.001 0.01 ±0.000 
BRAIN 0.01 ±0.000 0.00 ±0.000 0.00 ±0.000 
TUMOR/BLOOD 0.40 ±0.002 0.78 ±0.044 0.70 ±±0.008 
TUMOR/MUSCLE 1.96 ±0.015 5.32 ±0.402 3.35 ±0.147 
TUMOR/BRAIN 6.19 ±0.365 11.06 ±0.667 11.93 ±0.675 
______________________________________________________________________________ 
Value shown represents the mean  standard deviation of data from 3 animals 
[Applied Radiation and Isotopes 2013; 72: 105-113]  
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Table 3. Biodistribution of 
99
Tc-N4amG in breast tumor-bearing rats 
______________________________________________________________________________ 
% of injected dose per gram of tissue weight (n=3/time, interval, iv) 
    0.5 HR  2 HR  4 HR  
BLOOD 
 
1.47 
 
+0.03 
 
0.91 
 
+0.12 
 
0.61 
 
+0.09 
 
HEART 
 
0.41 
 
+0.06 
 
0.25 
 
+0.03 
 
0.17 
 
+0.03 
 
LUNG 
 
0.88 
 
+0.13 
 
0.61 
 
+0.14 
 
0.42 
 
+0.08 
 
THYROID 
 
0.67 
 
+0.02 
 
0.51 
 
+0.06 
 
0.38 
 
+0.09 
 
PANCREAS 
 
0.29 
 
+0.03 
 
0.19 
 
+0.04 
 
0.13 
 
+0.01 
 
LIVER 
 
8.39 
 
+2.26 
 
8.07 
 
+0.28 
 
8.25 
 
+1.30 
 
SPLEEN 
 
1.08 
 
+0.16 
 
1.12 
 
+0.21 
 
1.18 
 
+0.15 
 
KIDNEY 
 
4.30 
 
+0.57 
 
6.71 
 
+0.53 
 
7.06 
 
+1.04 
 
STOMACH 
 
0.37 
 
+0.05 
 
0.30 
 
+0.05 
 
0.24 
 
+0.02 
 
INTESTINE 
 
0.35 
 
+0.04 
 
0.24 
 
+0.04 
 
0.21 
 
+0.07 
 
UTERUS 
 
0.48 
 
+0.02 
 
0.31 
 
+0.06 
 
0.22 
 
+0.04 
 
TUMOR 
 
0.43 
 
+0.04 
 
0.37 
 
+0.06 
 
0.32 
 
+0.06 
 
MUSCLE 
 
0.13 
 
+0.03 
 
0.11 
 
+0.01 
 
0.07 
 
+0.02 
 
BONE 
 
0.96 
 
+0.07 
 
0.82 
 
+0.36 
 
1.02 
 
+0.21 
 
BRAIN 
 
0.04 
 
+0.01 
 
0.02 
 
+0.00 
 
0.02 
 
+0.01 
 
T/BLOOD 
 
0.29 
 
+0.02 
 
0.41 
 
+0.03 
 
0.52 
 
+0.02 
 
T/MUSCLE 
 
3.24 
 
+0.38 
 
3.49 
 
+0.41 
 
4.30 
 
+0.59 
 
________________________________________________________________________________ 
Value shown represent the mean  standard deviation of data from 3 animals 
[Applied Radiation and Isotopes 2013; 72: 105-113] 
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Table 4. Biodistribution of 
99
Tc-MIBI in breast tumor-bearing rats 
 
% of injected dose per gram of tissue weight (n=3/time, interval, iv) 
  15 MIN   45 MIN   2 HR   4 HR   
   MEAN  SEM  MEAN  SEM  MEAN  SEM  MEAN  SEM  
Blood  0.15 0.01 0.05 0.00 0.03 0.00 0.02 0.00 
Heart  4.30 0.27 3.69 0.31 3.60 0.14 3.48 0.05 
Lung  1.41 0.13 0.63 0.07 0.34 0.02 0.23 0.02 
Thyroid  2.06 0.20 1.45 0.08 1.06 0.07 0.94 0.03 
Pancreas 3.56 0.12 1.99 0.18 0.87 0.04 0.41 0.05 
Liver  1.91 0.11 0.83 0.02 0.33 0.05 0.33 0.01 
Spleen  1.91 0.09 0.91 0.05 0.58 0.02 0.35 0.03 
Kidney  7.43 0.71 4.25 0.34 2.28 0.21 1.73 0.10 
Stomach 2.76 0.17 1.80 0.10 1.50 0.05 1.37 0.13 
Intestine 1.72 0.10 0.95 0.07 0.77 0.11 0.45 0.04 
Uterus  0.68 0.05 0.48 0.02 0.35 0.01 0.29 0.03 
Tumor  0.61 0.03 0.37 0.02 0.24 0.03 0.21 0.02 
Muscle  0.54 0.02 0.63 0.02 0.59 0.06 0.57 0.03 
Bone  0.53 0.03 0.35 0.03 0.25 0.01 0.15 0.01 
Brain  0.04 0.00 0.02 0.00 0.01 0.00 0.01 0.00 
T/Blood 4.07 0.01 7.40 0.02 8.00 0.02 10.50 0.01 
T/Muscle 1.13 0.01 0.59 0.00 0.41 0.02 0.37 0.01 
 
Value shown represent the mean  SEM of data from 3 animals 
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Table 5. Biodistribution of 
99
Tc-MIBI in rat 
 
% of injected dose per gram of tissue weight (n=3/time, interval, iv) 
    5 MIN   30 MIN  
BLOOD 
 
0.12 
 
+0.01 
 
0.04 
 
+0.01 
 
HEART 
 
1.50 
 
+0.02 
 
1.61 
 
+0.18 
 
LUNG 
 
0.92 
 
+0.04 
 
0.49 
 
+0.00 
 
LIVER 
 
0.94 
 
+0.03 
 
0.83 
 
+0.11 
 
SPLEEN 
 
1.55 
 
+0.06 
 
1.09 
 
+0.05 
 
KIDNEY 
 
6.53 
 
+0.19 
 
2.38 
 
+0.34 
 
BRAIN 
 
0.03 
 
+0.01 
 
0.03 
 
+0.01 
 
HEART/BLOOD 
 
12.78 
 
 
 
   42.02 
 
 
 
HEART/LUNG 
 
1.68 
  
3.27 
  
_____________________________________________________________ 
Value shown represent the mean  standard deviation of data from 3 animals 
 
[Nuclear Medicine and Biology 1995; 22: 585-588]  
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3.2.2.6. Olinda Dosimetry Estimation 
The human residence time estimates were applied to the Olinda software to produce 
radiation dose estimates for 
99m
Tc-N4amG. The Olinda output was multiplied by a proposed 
human dose of 20 mCi for 
99m
Tc-N4amG to yield total absorbed dose from an imaging study 
(Table 6). Radiation exposure to the whole body, blood forming organs (red marrow, 
spleen), gonads (testes, ovaries), and effective dose equivalent for the proposed human 
single dose at 20 mCi fall below the limits of 3 rad annually and 5 rad total. The absorbed 
dose in all other organs (e.g., kidneys) was below the limits of single dose of 5 rad annually 
and 15 rad in total. 
99m
Tc-N4amG showed total rad absorbed by each organ was below the 
proposed annual and total limits. Compared to the radiation dosimetry of 
99m
Tc-MIBI (Table 
7) [103], 
99m
Tc-N4amG showed lower overall radiation absorption (effective dose: 1 
rem/mCi = 0.27 mSv/MBq). 
.  
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Table 6. Radiation dose estimates of the reference adult for 
99
Tc-N4amG  
Organs (5 rem annual/15 rem total) 
   target organ rad/mCi human dose (20mCi) 
 Adrenals 1.01E-02 0.202 
Brain 8.52E-04 0.017 
Breasts 2.09E-03 0.042 
Gall bladder wall 1.03E-02 0.206 
LLI wall 9.35E-04 0.019 
Small int 3.56E-03 0.071 
Stomach 7.11E-03 0.142 
ULI wall 3.53E-03 0.071 
Heart wall 1.66E-02 0.332 
Kidneys 7.60E-02 1.520 
Liver 2.83E-02 0.566 
Lungs 1.55E-02 0.310 
Muscle 2.15E-03 0.043 
Pancreas 1.23E-02 0.246 
Bone surfaces 1.19E-02 0.238 
Skin 9.45E-04 0.019 
Testes 1.86E-04 0.004 
Thymus 3.30E-03 0.066 
Thyroid 7.62E-04 0.015 
Urine bladder wall 4.18E-04 0.008 
Uterus 1.06E-03 0.021 
EFF dose 6.79E-03 0.136 
 
Blood-forming organs (3 rem annual/ 5 rem 
total) 
target organ rad/mCi human dose (20mCi) 
 
Ovaries 1.24E-03 0.025 
Red marrow 3.07E-03 0.061 
Spleen 5.45E-02 1.090 
EFF dose equivalent 1.45E-02 0.290 
Total body 3.73E-03 0.075 
 
[Applied Radiation and Isotopes 2013; 72: 105-113]  
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Table 7. Radiation dosimetry for 
99
Tc-MIBI in adults 
 
ICRP: International Commission on Radiological Protection  
RIDIC: Radiation Internal Dose Information Center  
[Journal of Nuclear Medicine 2008; 49:1555–1563]  
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3.2.2.7. Scintigraphic Imaging Studies 
In planar imaging studies, the tumors could be well visualized in 13762 breast 
tumor-bearing rats (Figure 24). From computer outlined region of interest analysis, the 
average tumor-to-muscle count density ratios (n=3 rats) at 1, 2 and 4 hr were 3.69±0.15, 
3.96±0.52 and 4.93±0.79, respectively. There was a gradually linear increased tumor-to-
muscle count density ratio (p<0.1, compared to 1 hour T/M ratio) indicating the tumor 
targeting potential of 
99m
Tc-N4amG. 
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Figure 24. Planar scintigraphy of 
99m
Tc-N4amG in breast tumor-bearing rats at 1-4 hours.  
 
The numbers indicate tumor-to-muscle ratios (counts/pixel). Data showed that 
99m
Tc-
N4amG could gradually accumulate inside tumor (p<0.1). Reprinted with permission from 
Tsao N, Chanda M, Yu DF, Kurihara H, Zhang YH, Mendez R, Yang DJ (2013). 
99m
Tc-
N4amG: Synthesis Biodistribution and Imaging in Breast Tumor-bearing Rodents. Applied 
Radiation and Isotopes 72: 105-113.  
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3.2.2.8. Scintigraphic Imaging Studies Pre- and Post- Treatment 
To demonstrate the application of 
99m
Tc-N4amG in monitoring treatment response, 
three 13762 breast tumor-bearing rats were administered with 
99m
Tc-N4amG at pre- and 
post-paclitaxel treatment at 48 hours.  In images, the tumors could be well visualized in 
breast tumor-bearing rats.  From computer outlined region of interest analysis, the average 
tumor-to-muscle count density ratios at 1 and 4 hour was 3.69±0.15and 4.93±0.79 (before 
paclitaxel therapy) and changed to 1.68±0.13 and 2.21±0.68 (post-paclitaxel therapy).   
 
There was decreased tumor-to-muscle count density ratios (p<0.01, avg. 45-72%) 
post-paclitaxel treatment determined by 
99m
Tc-N4amG at 1-4 hour.  We previously have 
reported that the timing of apoptosis occurred at earlier time interval on day 2-3 post-paclitaxel 
treatment [96], which was supported by histopathology. Though the decrease in radionuclide 
retention from tumor-to-muscle count density ratios before and after paclitaxel treatment is 
minimal, this might be due to apoptosis occurred at earlier time. This data indicated the 
treatment monitoring ability of 
99m
Tc-N4amG (Figure 25).   
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Figure 25. Planar images of 
99m
Tc-N4amG at pre- and 72 hour post-treatment with 
paclitaxel (20 mg/kg, iv.). 
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3.2.2.9. Scintigraphic Imaging Studies Tumor/Inflammation Animal Model 
To demonstrate differential diagnosis of 
99m
Tc-N4amG between tumor and 
inflammation, the left legs of 13762 breast tumor-bearing rats were bearing with turpentine-
induced inflammation. The average tumor-to-inflammation count density ratio reached 1.90 
± 0.39 at 4 hours imaging (Figure 26).  
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Figure 26. Comparison of tumor-to-muscle and inflammation-to-muscle ratios using 13762 
breast tumor-bearing rats with inflammation.   
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3.2.2.10. Ki-67 Staining 
Ki-67 staining showed more than 80% Ki-67 positive cells in 13762 tumors. After 48 
hours paclitaxel (60mg/kg, iv., single injection) treatment, tumors were shrinking and Ki-67 
showed less than 20% positive cells (Figure 27). The correlation between Ki-67 staining and 
99m
Tc-N4amG uptake suggested that 
99m
Tc-N4amG could be used as a proliferation marker.  
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Figure 27. H&E and Ki-67 staining of tumor samples, pre- and post-treatment with 
paclitaxel. 
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3.2.2.11. Kinetic Study of Blood Clearance of 
99m
Tc-N4amG in Rats 
To determine blood clearance and biological half-life of 
99m
Tc-N4amG, Fischer-344 
rats were administered 
99m
Tc-N4amG. The blood clearance of 
99m
Tc-N4amG showed both 
distribution phase and elimination phase (Figure 28).  The elimination phase was used to 
calculate the biological half-life (t1/2) of 
99m
Tc-N4amG.  Regression line formulation (y=-
0.0078x+1.1329, R² = 0.9145) was estimated using Microsoft Office Excel 2003.  The 
biological t1/2 of 
99m
Tc-N4amG was 63.72 minutes.  
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Figure 28. 
99m
Tc-N4amG blood clearance in rat. 
 
The biological t1/2 of 
99m
Tc-N4amG was 63.72 minutes.  
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3.2.2.12. Radiolabeling of N4amG with 
68
Ga 
Radio-HPLC data showed the radiochemical purity of 
68
Ga-N4amG was greater than 
95%. There was no impurity observed in the spectrum (Figure 29). 
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Figure 29. Radio-HPLC analysis of 
68
Ga-N4amG. 
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3.2.2.13. In Vitro Cell Culture Assay 
To evaluate whether 
68
Ga-N4amG can penetrate the cell membrane, an in vitro 
cellular uptake study using 
68
Ga-N4amG and its chelator control (
68
Ga-N4) was conducted. 
High cellular uptake (up to 5.8%ID at 4 hour) of 
99m
Tc-N4amG in 13762 rat breast tumor 
cells was observed (Figure 30). The accumulation increased as a function of time suggesting 
68
Ga-N4amG has tumor targeting potential.  
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Figure 30. Cellular uptake of 
68
Ga-N4amG. 
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3.3. Discussion 
N4amG was synthesized through a 9-step synthetic route. The overall synthetic yield 
of N4amG was 6%. There were two low-yield steps involved in the synthetic route. The first 
low-yield step was in the very first synthetic step. As mentioned earlier, the hydroxyl group 
is crucial for the phosphorylation of N4amG. The phosphorylated N4amG is trapped inside 
the cell and involves in the DNA synthesis. Thus, one of the hydroxyl groups must be 
preserved during the synthesis. In other words, selectively protecting one of these two 
symmetric hydroxyl groups was necessary in the first step. Taking the advantage of the 
spatial blocking effect, a bulky protection group, methoxytrityl group, was chosen in the 
first stop to selectively protect one of the two hydroxyl groups. Unfortunately, this strategy 
caused low yield because single protected product (desired product) and double protected 
product (impurity) were competitive with each other. Longer reaction time favors the double 
protected product; meanwhile, shorter reaction time results in a large amount of non-reacted 
starting materials. The yield of the first step was about 40%. The impurities were mainly 
non-reacted penciclovir and double protected compounds. The second low-yield step was 
tosylation (the second step).  The yield of tosylation of alcohol is usually around 50%. 
Considering there was a bulky methoxytrityl group beside the hydroxyl group; the spatial 
blocking effect would reduce the reaction yield to 34%. The rest of the steps gave pretty 
good yield from 75%-95%.  
 
Many efforts have been made to synthesize direct linkage of N4-Guan (with carbon-
nitrogen linkage not amide linkage) from Bromo-Guan/Iodo-Guan with N4/N4-Oxalate. At 
least three different solvent systems (DMF, ethanol/H2O and acetonitrile), three different 
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bases (triethylamine in DMF, potassium carbonate and sodium hydroxide in ethanol/H2O 
and acetonitrile) and many other reaction conditions, including temperature, pH value and 
reaction time, have been tested. Unfortunately, none of these attempts worked. EC was then 
used to substitute N4 as the chelator for the reaction. EC-Guan was successfully synthesized 
under ethanol/H2O conditions in the presence of potassium carbonate. However, only 5.2 mg 
of EC-Guan was gained from 6 gram of penciclovir. The yield of EC-Guan was less than 1%.  
The reaction is a SN2 reaction, also known as bimolecular nucleophilic substitution. During 
the reaction, an intermediate of N4 (or EC) and Bromo-Guan forms before the leaving group 
(Br
-
) left. Formation of an intermediate is crucial in SN2 reactions. In my reaction, 
unfortunately, the bulky methoxytrityl group was located close enough to inhibit the 
formation of the intermediate. In other words, the reaction was not favorable because of the 
spatial blocking effect caused by the bulky protection group. There was an alternative. If the 
de-protection was performed before the reaction, there would be no spatial blocking effect. 
Nevertheless, unprotected Bromo-Guan could undergo an intermolecular SN2 reaction using 
its own unprotected hydroxyl group or amino group to eliminate its bromine. Since 
intermolecular reaction is much faster than intramolecular reaction, the yield of desired 
compound is anticipated to be poor. 
 
It is crucial for a radiotracer to penetrate the cell membrane and accumulate inside 
the cell in order to properly image proliferating cells. In the in vitro cellular studies, results 
showed 
99m
Tc-N4amG penetrated the cell membrane and accumulated inside the cell in a 
gradually increased manner. The uptake %ID reached 9 after three hours of incubation and 
17 after four hours.  Inside cells, about 40% intracellular 
99m
Tc-N4amG was located in the 
107 
 
nucleus. In addition, guanine, but not glucose, could significantly block the cellular uptake 
of 
99m
Tc-N4amG. It is known that penciclovir can penetrate the cell membrane through 
hNTs. Furthermore, inside cells, phosphorylated penciclovir can be recognized as dGMP 
and thereby involved in DNA synthesis [54]. With the same nucleoside backbone, 
99m
Tc-
N4amG may work very similarly to penciclovir inside cells. These results indicated that 
99m
Tc-N4amG could penetrate the cell membrane through NTs [54],  and involve in nucleus 
activity. Various nucleoside drugs, including penciclovir, fludarabine and gemcitabine, have 
all been proven to enter cells via NTs [54, 104]. Furthermore, Paproski, et al. demonstrated 
NTs play important role in mediating 
18
F-FLT uptake both in vitro and in vivo [36, 37]. 
Therefore, 
99m
Tc-N4amG can penetrate cell membrane most likely through nucleoside 
transporters.  
 
Two human protein families have been identified in uptake of nucleosides: human 
Equilibrative Nucleoside Transporter proteins (hENTs) and human Concentrative 
Nucleoside Transporter proteins (hCNTs). hENTs are sodium-independent, facilitated 
diffusion bidirectional carriers and consist of four members (ENT1-4) [105]. hCNTs are 
sodium-dependent, unidirectional active transporters and consist of three members (CNT1-
3) [106].  In hENTs, hENT1 and hENT2 are well-characterized transporters. Both have 
broad tissue distribution and wide range of transporting nucleosides (Table 8), including 
both purines and pyrimidines [107, 108]. It is also known that higher abundance of hENT1 
protein expression is associated with higher proliferation rate [109, 110]. hENT3 and 
hENT4 are two new members of hENTs. hENT3 is a lysosomal transporter working in a 
pH-dependent manner with the optimal pH value of 5.5 [111]. In addition, hENT3 has broad 
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substrate selectivity but is relatively insensitive. Similarly, hENT4 can transport adenosine 
in acidic condition with low sensitivity [112]. Compared with hENTs, hCNTs have higher 
affinity with their substrates and are also more selective in terms of substrates [105]. hCNT1 
prefers pyrimidine nucleosides, and hCNT2 prefers purine nucleosides [113]. hCNT3 
translocates both purine and pyrimidine nucleosides. Furthermore, hCNTs are very abundant 
in specialized epithelial tissues including liver, kidney and intestine [114-116]. hCNT2 are 
widespread in brain, whereas hCNT1 and hCNT3 are limited in some regions of brain [117].  
Since most hNTs are widespread among tissues, and the substrates selectivity is low, hNT-
specific inhibitors such as dilazep, which inhibits hENT1 and hENT2, and NBMPR, which 
inhibits only hENT, can be used to identify the roles of different subtype of hNTs in 
nucleoside analogues uptake [118]. 
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Table 8. Tissue and cellular distribution of nucleoside transporters.   
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In a cell sorting assay, the ideal way to perform this study is to incubate cells with 
radiotracers and then sort cells into different cell cycle phases. After sorting, one counts the 
activity of each stage of cells to obtain the correlation between cell uptake and cell cycle 
stages. However, to avoid radiation contamination of the FACS machine, it is prohibited to 
sort cells after radiotracer incubation. Therefore, the second best way to conduct this study is 
to sort cells first and then incubate radiotracers with these already sorted cells in suspension 
condition. The suspended cells may not perform exactly as they do when they are attached. 
This is a technical limitation that is difficult to overcome.  Even so, the results from this 
study can still provide an idea that 
99m
Tc-N4amG is an S phase-preferred agent. This uptake 
pattern is also found in many nucleoside-based chemotherapy agents [119].  
 
In animal studies, biodistribution results showed relatively high uptake in bone and 
spleen (1.02±0.21 and 1.18±0.15 %ID per gram of tissue weight at 4 hour, respectively.) As 
bone marrow and spleen are both blood forming organs, it suggests that 
99m
Tc-N4amG can 
target highly proliferating cells. Furthermore, as an imaging agent, in vivo imaging will be 
the ultimate method to evaluate its feasibility for clinical applications. Our animal imaging 
studies showed that 
99m
Tc-N4amG can actively accumulate in tumor. The tumor-to-muscle 
ratio increased as a function of time. It reached 4.93±0.79 at 4 hour after injection. 
99m
Tc-
N4amG can also monitor treatment outcome because it could differentiate tumor from 
inflammation and it was highly correlated to proliferation marker, Ki-67. These animal 
study results along with in vitro cell culture data suggest that 
99m
Tc-N4amG is a potential 
cell proliferation marker for future malignant diseases assessment. 
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In conclusion, N4amG, a novel nucleoside-based imaging tracer, can target tumor 
cell proliferation, for which good imaging agents are currently not available. The results 
demonstrated that N4amG can be synthesized in an appropriate yield and it can be labeled 
with 
99m
Tc and 
68
Ga in high radiochemical yield and purity. In vitro and in vivo biological 
evaluations showed it is feasible to use 
99m
Tc-N4amG in tumor specific imaging. 
  
112 
 
CHAPTER 4: 
99m
Tc-GLYCOPEPTIDE(GP) AS A GLUTAMATE TRANSPORTER 
TARGETING AGENT FOR PLANAR IMAGING 
 
 
Portions of this work have been published in Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-
C, Yu
 
D-F, Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and imaging in 
breast tumor-bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
  
113 
 
4.1. Rationale and Study Design 
Chitosan is known as a biocompatible polymer with wound healing, anti-infection, 
anti- inflammatory and tissue adhesive abilities [80-82]. In order to enhance the cell 
membrane penetrating ability and the therapeutic index of chitosan in cancer treatment, 
glutamate peptide was conjugated with chitosan. Glutamate is a potent neurotransmitter in 
the central nervous system and exerts its action via glutamate transporters [85]. It is also 
known that cellular uptake of glutamate peptide is specific to glutamate transporter [86].  
Conjugation of glutamate peptide with chitosan resulting GP would be a novel agent to 
target tumor vascular and cellular component. 
 
Each synthesized chemical was carefully purified and characterized using NMR, 
element analysis and GPC. Since GP has a character of polymer, the capillary 
electrophoresis was also used to investigate the purity. In addition, to determine the binding 
site of 
99m
Tc in GP, cold Re-glutamate peptide was synthesized. NMR analysis was used to 
determine the structure and binding site of Re. The radiochemical purity and stability of 
each radiolabeled compounds were tested by radio-HPLC and radio-TLC.  
 
To investigate the pharmacology of 
99m
Tc-GP, a series of in vitro and in vivo studies 
using 13762 cells were conducted. In vitro cellular uptake study was conducted to test the 
cell penetrating ability of 
99m
Tc-GP. A cellular fraction study and an in vitro blocking study 
using glutamic acid as a competitive blocker were conducted to investigate the uptake 
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mechanism. Furthermore, in vitro cellular uptake assay pre- and post- paclitaxel treatment 
study was performed to demonstrate the ability of using 
99m
Tc-GP in treatment monitoring.  
 
A biodistribution study using 13762 tumor-bearing rats was conducted to evaluate 
the exact tumor and organ uptake of 
99m
Tc-GP ex vivo. The distribution of radiotracer in 
each organ was expressed as percentage of the injected dose per gram of tissue (%ID/g).  
Tumor-to-normal tissue count ratios were determined from the corresponding %ID/g values. 
The result of the rat biodistribution study was further used to estimate human radiation 
absorption dose by MIRDose 3.1 software.  
 
An in vivo animal imaging study was conducted to investigate the tumor targeting 
potential of 
99m
Tc-GP. Tumor-to-muscle count density ratios were determined by dividing 
ROI measures (in counts per pixel) of tumor by the measures in a symmetric normal muscle 
site.  The ratios were used to evaluate the potential of 
99m
Tc-GP in tumor uptake. In addition, 
99m
Tc-GP was used to image tumor-bearing rats before and after paclitaxel treatment. This 
study was performed to evaluate the treatment monitoring ability of 
99m
Tc-GP. Furthermore, 
inflammation and tumor dual-bearing rats were used to investigate the tumor specificity of 
99m
Tc-GP. To determine the important pharmacological factor, i.e., biological half-life of 
99m
Tc-GP in blood, a blood clearance study was also performed. 
 
In statistical analysis, percent of injected dose per gram of tissue weight (%ID/g) and 
tumor-to-tissue ratios used in ex vivo biodistribution studies were presented as mean ± S.D.   
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The uptake of 
99m
Tc-GP in different conditions was compared using the Student’s t-test.  
Differences were considered to be statistically significant for a two-tailed p<0.05.  
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4.2. Results 
4.2.1. Chemistry and Radiochemistry 
4.2.1.1 Synthesis of Glycopeptide (GP) 
Unlike high molecular weight chitosan (MW>100,000), low molecular weight 
chitosan (MW 3,500-5,000, 75% deacetylated) is water soluble.  Glutamate peptide sodium 
salt is water soluble at pH 7.4.  GP conjugation was conducted in aqueous solution at pH7.4 
using water soluble 3-ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl as a coupling 
agent.  There was no gel formation under this reaction condition.  The chemical structure is 
shown in Figure 31.  Elemental analysis (two times) showed an average C: 41.54; H: 10:62; 
N: 7.19 (calculated C: 41.77; H: 8.86; N: 4.43).  From elemental analysis data, the estimated 
purity of GP was greater than 95% (based upon carbon content). Gel permeation 
chromatogram and capillary electrophoresis was used to analyze the purity of GP and the 
spectra are shown in Figure 32 and 33. The purities of the starting material chitosan and 
glutamate peptide were greater than 95%. 
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Figure 31. Structure and the element analysis of GP.  
 
Elemental analysis of GP (C11H14N2Na2O6, C, H, N) showed C: 41.54; H: 10:62; N: 7.19 
(calculated C: 41.77; H: 8.86; N: 4.43).  The estimated purity of GP was greater than 95% 
(based upon carbon content).   
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Figure 32. Gel permeation chromatogram analysis of GP. 
 
The retention time of GP was 9.645 minutes. 
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Figure 33. Capillary electrophoresis analysis of GP.   
 
The purity of the starting material chitosan and glutamate peptide were greater than 95%. 
Reprinted with permission from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, 
Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and imaging in breast tumor-
bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
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4.2.1.2. Synthesis of Re-GAP 
To determine the binding site of 
99m
Tc in GP, rhenium oxotrichloride (ReOCl3) and 
triphenylphosphine were used in the cold Re chemistry. 
 
The estimated NMR (proton and 
13
C) spectra of position 3-5 in GAP are shown in 
left panel of Figure 34 and at the terminal are shown in the middle.  The actual NMR spectra 
of proton and 
13
C of Re-GAP are shown in right panel.  Our data indicated that Re binds to 
GP at the position 3-5 in GAP. The findings suggest that the similar binding site may apply 
to 
99m
Tc.   
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Figure 34. NMR analysis of cold rhenium-oxo (ReO) (+3) in glutamate peptide.  
Compare to estimated spectra data, Re=O was found to bind to the glutamate peptide at the position 3-5. Reprinted with permission 
from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and 
imaging in breast tumor-bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
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4.2.1.3. Radiolabeling of GP with 
99m
Tc and In Vitro Stability Assays of 
99m
Tc-GP  
Radiolabeling of GP with 
99m
Tc was performed in a standard manner [93].  From 
radio-TLC (Bioscan, Washington, DC) analysis, the radiochemical purity was more than 
95% (Rf = 0.1). 
 
From radio-TLC analysis, the radiochemical purity was more than 95% (Rf = 0.1). In 
vitro stability assays indicated there was no breakdown of 
99m
Tc-GP up to 24 hours (Figure 
35). A minor breakdown fragment (<4%) was observed at 24 hour. The scale of each 
spectrum represents the intensity of radioactivity used. Various 
99m
Tc-GP samples were 
detected at the same time and analyzed by radio-TLC at various intervals. The scale 
intensity changes due to radioisotope decays. There are variations because radio-TLC 
analysis is to analyze radiochemical purity qualitatively. 
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Figure 35. In vitro stability assays of 
99m
Tc-GP.   
 
99m
Tc-GP was prepared in the concentration of 10mg/1mCi/1ml. 0.1 mL of 
99m
Tc-GP was 
incubated with 0.1 mL phosphate buffered saline (pH=7.4) at 0.5-24 hours. There was no 
breakdown of 
99m
Tc-GP up to 24 hours. Reprinted with permission from Wei, I-C, Tsao
 
N, 
Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, 
biodistribution and imaging in breast tumor-bearing rodents.  Applied Radiation and 
Isotopes 66:320-331. 
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4.2.2. Pharmacology and Toxicology 
4.2.2.1. In Vitro Cellular Uptake Assays 
To evaluate whether GP has tumor targeting potential and whether there is a 
correlation of uptake as a function of time, an in vitro cellular uptake assay was conducted.  
Data are expressed in mean ± S.D. percent of cellular uptake per mg of cell weight from 
three measurements. There was a gradually linear uptake of 
99m
Tc-GP in breast tumor cells 
suggesting 
99m
Tc-GP has tumor targeting potential (Figure 36).    
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Figure 36. In vitro cellular uptake of 
99m
Tc-GP.    
 
Reprinted with permission from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, 
Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and imaging in breast tumor-
bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
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4.2.2.2. In Vitro Cellular Fraction Assays  
To determine the distribution pattern of 
99m
Tc-GP within the cells, NE-PER 
extraction reagents were used for stepwise isolation of cytoplasmic and nuclear extracts 
from 13762 breast cancer cells.  Cytosolic fraction had 60% uptake of 
99m
Tc-GP whereas 
nucleus fraction had 40%.  Both nucleus and cytosolic fractions in 
99m
Tc-GP were higher 
than Na
99m
TcO4 (Figure 37). 
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Figure 37. Cellular fraction assay of 
99m
Tc-GP.  
 
After 2 ml of radioactive media containing 2 µCi (0.074 MBq) of
 99m
Tc-GP (0.02 mg/well) 
or sodium pertechnetate (control) was dispensed into each well of a 6-well plate. Cellular 
fractions were isolated by centrifugation. Cytosolic fraction had 60% uptake of 
99m
Tc-GP 
whereas nucleus fraction had 40%.  Both nucleus and cytosolic fractions in 
99m
Tc-GP were 
higher than Na
99m
TcO4. Reprinted with permission from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and 
imaging in breast tumor-bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
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4.2.2.3. In Vitro Cellular Uptake Assay of 
99m
Tc-GP, Pre- and Post- Treatment 
To determine whether 
99m
Tc-GP could monitor post-treatment changes, 13762 rat 
breast tumor cells (50,000 per each well) were incubated with paclitaxel (1-5 µM) for 48 
hours.  
99m
Tc-GP was able to measure uptake differences after cells were treated with 
paclitaxel (Figure 38).  TUNEL assays revealed that higher doses of paclitaxel induced more 
apoptosis (Figure 39).  The findings indicated that cellular uptake changes could be 
monitored by 
99m
Tc-GP.  
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Figure 38. In vitro cellular uptake 
99m
Tc-GP in pre- and post- treatment of paclitaxel.  
 
There was a decreased uptake after paclitaxel treatment (p<0.05).  The findings indicate that 
99m
Tc-GP was able to measure uptake differences after cells treated with paclitaxel. 
Reprinted with permission from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, 
Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and imaging in breast tumor-
bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
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Figure 39. TUNEL assays of breast tumor cells treated with paclitaxel (1-5 µM).   
 
The assays revealed that higher dose of paclitaxel induced more apoptosis. Reprinted with 
permission from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, Yang
 
DJ (2008).
 
99m
Tc-glycopeptide: synthesis, biodistribution and imaging in breast tumor-bearing rodents.  
Applied Radiation and Isotopes 66:320-331. 
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4.2.2.4. In Vitro Cellular Blocking Assay 
To determine whether cellular uptake of 
99m
Tc-GP was via a glutamate transporter, 
the 13762 rat breast tumor cells were incubated with glutamate (specific) or aspartate 
followed by 
99m
Tc-GP. There was decreased uptake in cells treated with glutamic acid but 
not with aspartic acid (Figure 40).  The results suggested that cellular uptake of 
99m
Tc-GP 
was via a glutamate transporter. 
 
  
132 
 
 
 
Figure 40. Cellular blocking assay of 
99m
Tc-GP.  
 
There was a dose-dependent decreased uptake in cells treated with glutamic acid, but not 
with aspartic acid.  The results indicated that cellular uptake of 
99m
Tc-GP was via a 
glutamate transporter. Reprinted with permission from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-
S, Wu
 
C-C, Yu
 
D-F, Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and 
imaging in breast tumor-bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
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4.2.2.5. Ex Vivo Biodistribution Studies 
There was an increased uptake in tumor-to-blood and tumor-to-muscle count density 
ratios in breast tumor-bearing rats.  The optimum tumor uptake and tumor-to-muscle count 
density ratios were 3-5 hours post-administrations.  There was no increased uptake in 
thyroid and stomach suggesting in vivo stability of 
99m
Tc-GP (Table 9).  
99m
Tc-GP was 
excreted through liver and kidneys.  
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Table 9. Biodistribution of 
99m
Tc-GP in breast tumor-bearing rats. 
 
 
 
[Applied Radiation and Isotopes 2008; 66:320-331]  
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4.2.2.6. MIRD Dosimetry Estimates 
The human residence time estimates were applied to the MIRDose 3.1 software 
package to produce radiation dose estimates for 
99m
Tc-GP (Table 10).  For 
99m
Tc-GP, the 
kidneys and spleen are the primary and secondary contributors, respectively.  The MIRD 
output was multiplied by a proposed human dose of 20 mCi for 
99m
Tc-GP to yield total 
absorbed dose from an imaging study.  
99m
Tc-GP showed total rad absorbed by each organ 
was below the proposed annual and total limits.  Based upon preclinical studies, dosimetry 
was estimated with MIRDose. Radiation exposure to the whole body, blood-forming organs 
(red marrow, spleen), gonads (testes, ovaries), and effective dose equivalent for the 
proposed human single dose at 20 mCi fall below the limits of 3 rad annually and 5 rad total. 
The absorbed dose in all other organs (e.g., kidneys) was below the limits of single dose of 5 
rad annually and 15 rad total. These radiation exposure values are commonly accepted as 
criteria for in vivo radiation safety measurement [98]. 
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Table 10. Radiation dose estimates of the reference adult for 
99m
Tc-GP 
 
[Applied Radiation and Isotopes 2008; 66:320-331]  
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4.2.2.7. Scintigraphic Imaging Studies 
To demonstrate the application of 
99m
Tc-GP in monitoring treatment response, three 
13762 breast tumor-bearing rats were administered with 
99m
Tc-GP (300 μCi/rat, 3 mg 
physical amount, iv) at pre- and post-paclitaxel treatment (60 mg/kg, iv, single dose) at 48 
hours. In images, the tumors could be well visualized in breast tumor-bearing rats.  From 
computer outlined region of interest analysis, the average tumor-to-muscle count density 
ratios at 0.5 and 1 hour was 3.67±0.60 and  3.85±0.60  (before paclitaxel therapy) and 
changed to 2.60±0.61 and 3.20±0.52 (post-paclitaxel therapy).   
 
There was decreased tumor-to-muscle count density ratios (p<0.05 at 1 hour, avg. 
17-30%) post-paclitaxel treatment determined by 
99m
Tc-GP at 0.5-1hour.  We previously 
have reported that the timing of apoptosis occurred at earlier time interval on day 2-3 post-
paclitaxel treatment [96] which was supported by histopathology. Though the decrease in 
radionuclide retention from tumor-to-muscle count density ratios before and after paclitaxel 
treatment is minimal, this might be due to apoptosis that occurred at an earlier time. The 
findings from this study indicated that 
99m
Tc-GP is useful in monitoring treatment response 
(Figure 41).   
  
138 
 
 
 
Figure 41.  Planar scintigraphy of 
99m
Tc-GP in breast tumor-bearing rats. 
 
Data showed that 
99m
Tc-GP could monitor treatment response. Reprinted with permission 
from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, Yang
 
DJ (2008).
 99m
Tc-
glycopeptide: synthesis, biodistribution and imaging in breast tumor-bearing rodents.  
Applied Radiation and Isotopes 66:320-331. 
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4.2.2.8. Scintigraphic Imaging Studies with and without Inflammation 
To demonstrate differential diagnosis of 
99m
Tc-GP between tumor and inflammation, 
the left legs of 13762 breast tumor-bearing rats were administered with turpentine (0.1 mL, 
i.m.). 
99m
Tc-GP had highest tumor and muscle as well as tumor and inflammation count 
density ratios compared to 
99m
Tc-chitosan and 
99m
Tc-glutamate peptide (Figure 42). 
99m
Tc-
GP was able to differentiate tumor and inflammation. 
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Figure 42. Planar scintigraphy of 
99m
Tc-chitosan (left two rats), 
99m
Tc-glutamate peptide and  
99m
Tc-GP in breast tumor-bearing rats with and without turpentine-induced inflammation.   
 
The data showed that 
99m
Tc-GP had highest tumor and muscle as well as tumor and 
inflammation count density ratios compared to 
99m
Tc-chitosan and 
99m
Tc-glutamate peptide. 
Reprinted with permission from Wei, I-C, Tsao
 
N, Huang
 
Y-H, Ho
 
Y-S, Wu
 
C-C, Yu
 
D-F, 
Yang
 
DJ (2008).
 99m
Tc-glycopeptide: synthesis, biodistribution and imaging in breast tumor-
bearing rodents.  Applied Radiation and Isotopes 66:320-331. 
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4.2.2.9. Kinetic Study of Blood Clearance of 
99m
Tc-GP in New Zealand White Rabbit 
To determine blood clearance and biological half-life of 
99m
Tc-GP, New Zealand 
white rabbits were administered intravenously with 
99m
Tc-GP. The blood clearance of 
99m
Tc-
GP showed both distribution phase and elimination phase (Figure 43).  The elimination 
phase was used to calculate the biological half-life (t1/2) of 
99m
Tc-GP. Regression line 
formulation (y=-0.0016x+0.2505, R² = 0.952) was estimated using Microsoft Office Excel 
2003.  The biological t1/2 of 
99m
Tc-GP was 1.30 hr.  
  
142 
 
 
 
 
Figure 43. Blood clearance (left panel) and biological half-life analysis of
 99m
Tc-GP.  
 
The biological half-life of 
99m
Tc-GP was 1.30 hours. 
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4.3. Discussion 
In 
99m
Tc labeling, tin (II) chloride was used to reduce sodium pertechnetate. 
However, in rhenium chemistry, the similar condition using tin (II) chloride as reduction 
agent was not achievable. In order to label 
99m
Tc, since the amount of sodium pertechnetate 
was considered as trace amount, 0.1mg of tin (II) chloride was more than enough to reduce 
the entire pertechnetate for labeling. But reduction of cold sodium perrhenate needs more 
quantity of tin (II) chloride due to differences in redox potential [120]. Larger amount of tin 
(II) chloride in the aqueous solution, however, causes colloidal particles. Besides, the pH 
conditions during the reduction are various [120, 121]. Such various pH conditions may not 
favorable for GP labeling. It is known that rhenium oxotrichloride (ReOCl3) and 
triphenylphosphine (a reducing agent) were the chemicals of choices in cold Re chemistry 
[122]. Therefore, rhenium oxotrichloride and triphenylphosphine instead of sodium 
perrhenate and tin (II) chloride were adopted to make cold Re-GAP. Our NMR analysis 
showed that rhenium bond to glutamate peptide at the position 3-5.  
 
Chitin is the second most abundant natural biopolymer in the world. It is also the 
most abundant naturally occurring polysaccharide with amino sugars. Chitosan is derived by 
deacetylation of chitin. The difference between chitosan and chitin is the degree of 
deacetylation. Chitosan is generally defined as chitin with more than 70% deacetylation rate. 
The higher the deacetylation rate, the better physical and chemical properties that chitosan 
has. The amino groups make it possible for chitosan to be chemically modified.  Chitosan 
derivatives are used widely in the pharmaceutical field as drug carriers and excipients. For 
instance, intratumoral administration of gadopentetic acid-chitosan complex nanoparticles 
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has been used for gadolinium neutron-capture therapy. Chitosan has been applied in drug 
delivery [123-125]. It has been reported that chitosan was modified with thioglycolic acid 
(TGA) to form chitosan-TGA conjugates. The promising physicochemical properties of  
Chitosan-thioglycolic acid conjugates make this chitosan derivative a suitable candidate in 
tissue engineering [126]. Despite the various applications of chitosan derivatives, one major 
limitation of chitosan is lack of cellular targeting and cellular penetrating abilities.   
 
A previous study has shown that radiolabeled glutamic acid is useful in tumor 
cellular imaging [127]. In addition, glutamate peptide has been developed to conjugate with 
drug for delivery [128, 129].
 
To optimize the intracellular uptake of chitosan derivatives, 
glutamate peptide was conjugated to chitosan resulting GP copolymer. This copolymer was 
first designed as a tumor targeting drug carrier for its amino and/or carboxylic acid groups 
are suitable for conjugating with a broad spectrum of anticancer drugs with either amino or 
acid groups. GP provides advantages over either chitosan or glutamate peptide along.  
Moreover, GP could be easily labeled with radioisotopes, such as 
99m
Tc or 
68
Ga. This 
multifunction biodegradable copolymer is a candidate of imaging guided therapy carrier. 
 
Our in vitro radiolabeling stability assay demonstrated that 
99m
Tc can be stably 
labeled with GP for up to 24 hours. We believe it should be attributed to the abundant 
carboxylic acids from glutamate peptide, which stabilize 
99m
Tc. Consider another multi-
carboxylic acid chelator, diethylenetriamine pentaacetic acid (DTPA). DTPA can be labeled 
with 
99m
Tc with high radiochemical purity and stability [130].  Several compounds have 
been reported to show high 
99m
Tc labeling stability with DTPA as a chelator [93, 131, 132].
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In addition, DTPA can be labeled with other radioisotopes for different imaging modalities.  
For instance, 
61
Cu and 
64
Cu are used for PET imaging [133], gadolinium for MRI [134, 
135], and 
188
Re for internal radiation therapy [136]. Due to the similar chemical properties 
that glutamate peptide and DTPA are shared, GP is an idea material for radioisotopes 
labeling. 
 
In the in vitro cellular blocking study, results showed 
99m
Tc-GP could penetrate the 
cell membrane and accumulate inside the cell. Inside cells, about 40% uptake 
99m
Tc-GP was 
located in the nucleus. In addition, glutamic acid, but not aspartic acid, can specifically 
block 
99m
Tc-GP uptake.  It indicates GP uptake is through glutamate transporters.  
 
To further investigate whether 
99m
Tc-GP could be used to monitor treatment 
response, we used paclitaxel to treat tumor cells for in vitro cell culture studies and in vivo 
imaging studies. Our data demonstrated that 
99m
Tc-GP was able to measure uptake 
differences after cells treated with paclitaxel in vitro and in vivo. In vitro cell culture results 
showed that there was a decrease in cellular uptake of 
99m
Tc-GP. Moreover, from TUNEL 
assay, there was an increase in apoptotic cell numbers with increasing concentration of 
paclitaxel. Since TUNEL assay is to detect DNA fragmentation by labeling the terminal end 
of nucleic acids, TUNEL assay positive cells are considered as apoptotic cells. In vitro cell 
culture data implied that the differences between cell uptake before and after paclitaxel 
treatment might due to the different numbers of apoptotic cells killed by paclitaxel. In vivo 
imaging studies using tumor-bearing rats pre- and post- paclitaxel treatment also showed 
that there was a 17-30% decrease in tumor-to-muscle count density ratios after paclitaxel 
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treatment. Our previous histopathology finding evidence showed the timing of apoptosis 
occurred at earlier time interval on day 2-3 post-paclitaxel treatment [96], 
99m
Tc-GP may be 
useful in monitoring tumor apoptosis. Collectively, in vitro and in vivo findings suggested 
that 
99m
Tc-GP is useful in monitoring drug-induced apoptosis not only in paclitaxel but also 
in other chemotherapy drugs. GP, as a targeted drug carrier, may provide advantages not 
only to improve drug solubility but also to overcome drug resistance during chemotherapy.   
 
In the biodistribution study, 
99m
Tc-GP showed high liver and renal uptake. From a 
drug metabolism point of view, that might be caused by the metabolic routes of chitosan and 
glutamate peptide inside animal body.  Chitosan and glutamate peptide were metabolized in 
liver and washed out though intestines and kidneys.  To overcome the high liver and renal 
uptake, 3-dimentional imaging modalities (such as SPECT) or dual imaging modalities 
(such as SPECT/CT) would be needed to assess lesions.  
 
In summary, 
99m
Tc-GP can penetrate cell membrane through glutamate transporter. 
The in vitro and in vivo data suggested that it is feasible to use 
99m
Tc-GP in tumor 
assessment.   
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CHAPTER 5:  
68
Ga-GP AS A GLUTAMATE TRANSPORTER TARGETING 
AGENT FOR PET IMAGING 
 
 
Portions of this work have been published in Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, 
Yu D, Yang DJ (2011). Development of 
68
Ga-Glycopeptide as an imaging probe for tumor 
angiogenesis. Journal of Biomedicine and Biotechnology 2011:267206, doi: 
10.1155/2011/267206.  PMID:21541212; PMCID: PMC3085313 
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5.1. Rational and Study Design 
In Chapter 4, I have discussed that GP, a copolymer of chitosan and glutamate 
peptide, could target tumor vasculature and cellular through glutamate transporters [92].   In 
vitro cellular assays showed that cell uptake of 
99m
Tc-GP was via glutamate transporters.  
The biodistribution study revealed increased tumor-to-tissue count ratios as a function of 
time. 
99m
Tc-GP could be used to measure tumor uptake changes before and after paclitaxel 
treatment.  In vitro and in vivo studies confirmed that it is feasible to use 
99m
Tc-GP for tumor 
imaging.  To evaluate whether GP could also be labeled with 
68
Ga for PET imaging, the 
radiochemical stability, tissue distribution and tumor imaging potential of 
68
Ga-GP were 
studied. 
 
The radiochemical purity and stability of 
68
Ga-GP was tested by radio-TLC. A 
biodistribution study using 13762 tumor-bearing rats was conducted to evaluate the exact 
tumor and organ uptake of 
68
Ga-GP ex vivo. The distribution of radiotracer in each organ 
was expressed as percentage of the injected dose per gram of tissue (%ID/g).  Tumor-to-
normal tissue count ratios were determined from the corresponding %ID/g values. The result 
of the rat biodistribution study was further used to estimate human radiation absorption dose 
by MIRDose 3.1 software.  
 
In vivo PET imaging studies were conducted in both 13762 tumor-bearing rats and 
VX2 tumor-bearing New Zealand white rabbits using 
68
Ga-GP and 
18
F-FDG to investigate 
the tumor targeting potential of 
68
Ga-GP. Tumor standardized uptake values (SUVs) and 
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dynamic tumor uptakes of both 
68
Ga-GP and 
18
F-FDG were calculated.  To determine the 
important pharmacological factor, i.e., biological half-life of 
68
Ga-GP in blood, blood 
clearance study was also performed. 
 
In statistical analysis, percent of injected dose per gram of tissue weight (%ID/g) and 
tumor-to-tissue ratios used in ex vivo biodistribution studies were presented as mean ± S.D.    
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5.2. Results 
5.2.1. Chemistry and Radiochemistry 
5.2.1.1. Radiolabeling of GP with 
68
Ga and Stability Assay 
Radiolabeling of GP with 
68
Ga was performed in a standard manner [94]. From 
radio-TLC (Bioscan, Washington, DC) analysis, the radiochemical purity was more than 
95% (Rf = 0.1).  
 
68
Ga-GP was prepared in the concentration of 5mg/1mCi/ml.  0.1mL of 
68
Ga-GP was 
incubated with 0.1mL phosphate buffered saline (pH=7.4) at 37 ºC for 30-120min. In vitro 
stability assays indicated that the radiation yield is 98.67% at 30 min and 97.73% at 2 hr 
after labeling. There was no breakdown of 
68
Ga-GP up to 2 hr (Figure 44). 
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Figure 44. In vitro radiochemical stability test of 
68
Ga-GP.  
 
68
Ga-GP was prepared in the concentration of 5 mg/1 mCi/mL. 0.1 mL of 
68
Ga-GP was 
incubated with 0.1 mL phosphate buffered saline (pH=7.4) at 30-120 minutes. There was no 
breakdown of 
68
Ga-GP up to 120 minutes. Reprinted with permission from Tsao N, Wang C, 
Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 
68
Ga-Glycopeptide as 
an imaging probe for tumor angiogenesis. Journal of Biomedicine and Biotechnology 
2011:267206, doi: 10.1155/2011/267206.  PMID:21541212; PMCID: PMC3085313.
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5.2.2. Pharmacology and Toxicology 
5.2.2.1. Biodistribution Studies 
There was an increased uptake in tumors (percent of injected dose per gram of 
tissue), tumor-to-blood and tumor-to-muscle count density ratios by 
68
Ga-GP at 0.5-2 hours 
whereas the optimum tumor uptake and tumor-to-muscle count density ratios for 
18
F-FDG 
were at 1 hour post-administrations.  In biodistribution studies at 30, 60, 120 minutes, tumor 
uptake values, tumor/blood and tumor/muscle ratios for 
68
Ga-GP were 0.68±0.12 to 
1.18±0.09, 0.26±0.03 to 0.86±0.09 and 6.12±1.87 to 13.26±4.41; for
 18
F-FDG were 
2.03±0.18 to 2.49±0.08, 5.19±0.38 to 34.37±1.76 and 2.87±0.24 to 7.54±0.56, respectively 
(Tables 11 and 12).  
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Table 11. Biodistribution of 
68
Ga-GP in breast tumor-bearing rats  
 
% of injected dose per gram of tissue weight (n=3/time, interval, iv)
1
 
 30 MIN 60 MIN 120 MIN 
BLOOD 2.61 
 
±0.18 
 
1.81 
 
±0.05 
 
1.37 
 
±0.05 
 
HEART 
 
0.59 
 
±0.06 
 
0.43 
 
±0.02 
 
0.32 
 
±0.02 
 
LUNG 
 
2.34 
 
±0.45 
 
2.58 
 
±0.16 
 
1.38 
 
±0.06 
 
THYROID 
 
1.10 
 
±0.11 
 
1.40 
 
±0.87 
 
0.59 
 
±0.06 
 
PANCREAS 
 
0.38 
 
±0.03 
 
0.34 
 
±0.04 
 
0.28 
 
±0.02 
 
LIVER 
 
3.81 
 
±0.32 
 
4.83 
 
±0.54 
 
4.94 
 
±0.38 
 
SPLEEN 
 
2.13 
 
±0.07 
 
2.65 
 
±0.14 
 
2.97 
 
±0.11 
 
KIDNEY 
 
1.35 
 
±0.02 
 
1.36 
 
±0.01 
 
1.41 
 
±0.11 
 
STOMACH 
 
0.58 
 
±0.04 
 
0.65 
 
±0.07 
 
0.74 
 
±0.18 
 
INTESTINE 
 
0.54 
 
±0.12 
 
0.53 
 
±0.07 
 
0.78 
 
±0.22 
 
UTERUS 
 
0.70 
 
±0.02 
 
0.65 
 
±0.05 
 
0.57 
 
±0.03 
 
TUMOR 
 
0.68 
 
±0.12 
 
0.89 
 
±0.10 
 
1.18 
 
±0.09 
 
MUSCLE 
 
0.12 
 
±0.02 
 
0.12 
 
±0.00 
 
0.10 
 
±0.02 
 
BONE 
 
0.45 
 
±0.12 
 
0.46 
 
±0.09 
 
0.59 
 
±0.03 
 
BRAIN 
 
0.08 
 
±0.01 
 
0.07 
 
±0.01 
 
0.07 
 
±0.01 
 
TUMOR/BLOOD 
 
0.26 
 
±0.03 
 
0.49 
 
±0.07 
 
0.86 
 
±0.09 
 
TUMOR/MUSCLE 
 
6.12 
 
±1.87 
 
7.20 
 
±0.83 
 
13.26 
 
±4.41 
 
1. Value shown represent the mean  standard deviation of data from 3 animals at (Count at 460-560 
keV window) 
 
[Journal of Biomedicine and Biotechnology 2011:267206]  
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Table 12. Biodistribution of 
18
F-FDG in breast tumor-bearing rats  
 
% of injected dose per gram of tissue weight (n=3/time, interval, i.v.)
1
 
  30 MIN 60 MIN 120 MIN 
BLOOD 0.40 ±0.04 0.13 ±0.01 0.06 ±0.00 
HEART 1.57 ±0.06 1.38 ±0.13 1.08 ±0.07 
LUNG 0.55 ±0.06 0.42 ±0.02 0.46 ±0.03 
THYROID 1.07 ±0.08 1.04 ±0.04 1.05 ±0.07 
PANCREAS 0.26 ±0.03 0.21 ±0.01 0.20 ±0.02 
LIVER 0.40 ±0.05 0.16 ±0.01 0.13 ±0.01 
SPLEEN 0.82 ±0.08 0.74 ±0.03 0.86 ±0.07 
KIDNEY 0.71 ±0.05 0.37 ±0.01 0.24 ±0.02 
STOMACH 0.61 ±0.08 0.44 ±0.03 0.39 ±0.03 
INTESTINE 0.69 ±0.07 0.53 ±0.03 0.52 ±0.02 
UTERUS 0.51 ±0.04 0.42 ±0.03 0.41 ±0.03 
TUMOR 2.13 ±0.11 2.49 ±0.08 2.03 ±0.18 
MUSCLE 0.33 ±0.04 0.34 ±0.03 0.74 ±0.02 
BONE 0.33 ±0.04 0.44 ±0.06 0.50 ±0.03 
BRAIN 2.00 ±0.15 1.99 ±0.05 1.39 ±0.09 
TUMOR/BLOOD 5.19 ±0.38 19.78 ±1.37 34.37 ±1.76 
TUMOR/MUSCLE 5.88 ±0.57 7.54 ±0.56 2.87 ±0.24 
 
1. Value shown represent the mean  standard deviation of data from 3 animals at (Count at 460-560 
keV window) 
 
[Journal of Biomedicine and Biotechnology 2011:267206]  
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5.2.2.2. MIRD Dosimetry Estimates 
The MIRD output was multiplied by a proposed human dose of 20 mCi for 
68
Ga-GP 
to yield total absorbed dose shown in Table 13.  
68
Ga-GP showed total rad absorbed by each 
organ was below the proposed annual and total limits.  Radiation exposure to the whole 
body, blood-forming organs (red marrow, spleen), gonads (testes, ovaries), and effective 
dose equivalent for the proposed human single dose at 20 mCi fall below the limits of 3 rad 
annually and 5 rad total. The absorbed dose in all other organs (e.g., kidneys) was below the 
limits of single dose of 5 rad annually and 15 rad total (Table 13).   These radiation exposure 
values are commonly accepted as criteria for in vivo radiation safety measurement. 
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Table 13. Radiation dose estimates of the reference adult for 
68
Ga-GP 
 
Radiation Dose Estimates of Reference Adult for 
68
Ga-GP from Rabbits 
ORGANS (5 rem annual/15 rem total)  
    
target organ rad/mCi human dose (mCi) rad 
adrenals 2.54E-04 20 0.005 
brain 7.37E-06 20 0.000 
breasts 2.78E-04 20 0.006 
gall bladder wall 1.03E-04 20 0.002 
lli wall 8.24E-06 20 0.000 
small int 2.34E-05 20 0.000 
stomach 1.69E-04 20 0.003 
uli wall 3.02E-05 20 0.001 
heart wall 2.30E-04 20 0.004 
kidneys 7.92E-05 20 0.002 
liver 2.13E-04 20 0.004 
lungs 4.62E-04 20 0.009 
muscle 9.27E-05 20 0.002 
pancreas 2.54E-04 20 0.005 
bone surfaces 8.54E-05 20 0.002 
skin 4.65E-05 20 0.001 
testes 2.09E-06 20 0.000 
thymus 8.81E-04 20 0.018 
thyroid 5.34E-05 20 0.001 
urine bladder wall 5.92E-06 20 0.000 
uterus 1.11E-05 20 0.000 
eff dose 1.48E-04 20 0.003 
BLOOD-FORMING ORGANS (3 rem annual/5 rem total) 
    
target organ rad/mCi human dose (mCi) rad 
ovaries 1.16E-05 20 0.000 
red marrow 1.29E-04 20 0.003 
spleen 1.18E-04 20 0.002 
eff dose eq 1.60E-03 20 0.032 
total body 1.92E-04 20 0.004 
 
[Journal of Biomedicine and Biotechnology 2011:267206]  
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5.2.2.3. PET Imaging Studies 
Tumors could be well visualized both in breast tumor-bearing rats and VX-2 tumor-
bearing rabbits (Figures 45 and 46).  From PET image ROI analysis, the SUVs for 
68
Ga-GP 
and 
18
F-FDG in VX-2 tumor-bearing rabbits were 3.25 and 7.04, respectively (Figures 47 and 
48). PET images in tumor-bearing rats and rabbits confirmed that 
68
Ga-GP could assess 
tumor uptake.  PET dynamic scan showed fast tumor uptake of 
68
Ga-GP in a New Zealand 
white rabbit bearing VX2 tumor (Figure 49). Furthermore, there is no intestine uptake in 
68
Ga-GP PET imaging indicated the radioisotope labeling of 
68
Ga-GP is stable in vivo. 
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Figure 45. Dynamic mPET imaging of 
68
Ga-GP (upper) and 
18
F-FDG (lower) in breast 
tumor bearing rats.  
 
Tumor could be visualized by both compounds. Reprinted with permission from Tsao N, 
Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 
68
Ga-
Glycopeptide as an imaging probe for tumor angiogenesis. Journal of Biomedicine and 
Biotechnology 2011:267206, doi: 10.1155/2011/267206.  PMID:21541212; PMCID: 
PMC3085313. 
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Figure 46.   PET Whole Body imaging at 45 min in New Zealand white rabbits bearing VX-
2 tumors. (T = tumor) 
 
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang 
DJ (2011). Development of 
68
Ga-Glycopeptide as an imaging probe for tumor angiogenesis. 
Journal of Biomedicine and Biotechnology 2011:267206, doi: 10.1155/2011/267206.  
PMID:21541212; PMCID: PMC3085313. 
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Figure 47. 45 minutes dynamic image with PET-CT of 
68
Ga-GP in a New Zealand white rabbit bearing VX-2 tumor showed SUV of 
the tumor was 3.25. 
 
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 
68
Ga-
Glycopeptide as an imaging probe for tumor angiogenesis. Journal of Biomedicine and Biotechnology 2011:267206, doi: 
10.1155/2011/267206.  PMID:21541212; PMCID: PMC3085313.
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Figure 48. 45 minutes dynamic image with PET-CT of 
18
FDG in New Zealand White 
Rabbit bearing VX2 tumor showed SUV of the tumor was 7.04. 
 
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang 
DJ (2011). Development of 
68
Ga-Glycopeptide as an imaging probe for tumor angiogenesis. 
Journal of Biomedicine and Biotechnology 2011:267206, doi: 10.1155/2011/267206.  
PMID:21541212; PMCID: PMC3085313. 
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Figure 49. 45 Minutes dynamic tumor uptake of 
68
Ga-GP in a New Zealand white rabbit 
bearing VX2 tumor.  
 
The axial view from PET-CT showed the location of tumor. Reprinted with permission from 
Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang DJ (2011). Development of 
68
Ga-
Glycopeptide as an imaging probe for tumor angiogenesis. Journal of Biomedicine and 
Biotechnology 2011:267206, doi: 10.1155/2011/267206.  PMID:21541212; PMCID: 
PMC3085313. 
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5.2.2.4. Kinetic Study of Blood Clearance of 
68
Ga-GP in New Zealand White Rabbit 
The blood clearance of 
68
Ga-GP showed both distribution phase and elimination 
phase (Figure 50).  The elimination phase was used to calculate the biological half-life of 
68
Ga-GP.  Regression line formulation (y = -0.0018x + 0.3967, R
2
 = 0.8375) was estimated 
using Microsoft Office Excel 2003.  The biological t1/2 of 
68
Ga-GP was 1.84 hour.  
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Figure 50. Blood clearance (left panel) and biological half-life analysis of
 68
Ga-GP showed 
the biological half-life of 
68
Ga-GP was 1.84 hour. 
 
Reprinted with permission from Tsao N, Wang C, Her L, Kai Tzen Y, Chen J, Yu D, Yang 
DJ (2011). Development of 
68
Ga-Glycopeptide as an imaging probe for tumor angiogenesis. 
Journal of Biomedicine and Biotechnology 2011:267206, doi: 10.1155/2011/267206.  
PMID:21541212; PMCID: PMC3085313. 
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5.3. Discussion 
In chapter 4, the rationale of GP design was mentioned. GP was designed for tumor 
targeting drug carrier purpose. The advantages of GP include: 1. GP is a biodegradable 
polymer, which has been proven to be no toxicity in animals even in high dose (data shown 
in Chapter 6). 2. GP is a copolymer of chitosan and glutamate peptide. Chitosan derivatives 
are used widely in the pharmaceutical field as drug carriers and excipients. Its wound 
healing ability and the adhesive property with vascular endothelial cell are reported [137, 
138]. 3. The glutamate peptide plays an important role in cellular targeting through 
glutamate transporter. Chitosan and glutamate peptide made GP a drug carrier with both 
vascular endothelial adhesiveness and cellular targets. 4. GP has abundant amino and 
carboxylic acid functional groups which are suitable for conjugating with a broad spectrum 
of anticancer drugs with either amino or carboxylic acid functional groups. This property 
expends the clinical application of GP-drug conjugates. 5. GP can be easily labeled with 
different radioisotopes. In 
68
Ga-GP radiochemical in vitro stability assay, it showed there 
was no breakdown of 
68
Ga-GP up to 2 hours after labeling. This data along with 
99m
Tc-GP 
stability data demonstrated that GP is a stable molecular with proper radioisotope labeling 
stabilities. 
 
The molecular weight range of GP was investigated. The optimal molecular weight 
range of GP is between 6,000-9,000 Da. With smaller molecular weight (<6,000 Da), GP 
may lose its drug delivery capacity and ability. On the other hand, with larger molecular 
weight (>9,000 Da), GP may lose its cellular penetrating ability via glutamate transporters 
and could also cause toxicity due to the prolonged circulation time. Chitosan, with a 
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molecular weight of 3,000-3,500 Da and with deacetylation rate greater than 75%, is 
preferred for GP synthesis. A molecular weight larger than 10,000 Da may cause chitosan 
insoluble in aqueous solution. Moreover, a lower deacetylation rate will not only affect the 
solubility but also provide less drug conjugation capacity. For glutamate peptide, 
oligopeptide with ten glutamate units (with molecular weight at 1,500 Da) is preferred.  It is 
known that a chain of five or more glutamic acids could reduce renal uptake in animal 
models [87]. During the reaction, chitosan and glutamate peptide with molar equivalent at 
1:2 would be used to synthesize GP.   
 
The biodistribution of 
68
Ga-GP was similar to 
99m
Tc-GP. Both of them had higher 
liver and kidney uptake. It may due to the metabolic path ways of both chitosan and 
glutamate peptide. The reason has been discussed in Chapter 4. For the dosimetry data, on 
the other hand, 
68
Ga-GP showed much lower radiation absorption dose (rad) in liver and 
kidney than 
99m
Tc-GP. This is because 
68
Ga has shorter biological half-life and the 
biodistribution was conducted only for 2 hours.  
 
In animal imaging studies, we compared 
68
Ga-GP and 
18
F-FDG in both 13762 tumor-
bearing rats and VX2 tumor-bearing rabbit animal models. In microPET imaging study, 
because of the large tumor mass, inside the tumor formed a region of necrosis area. 
68
Ga-GP 
only targeted outside living tumor cells but not the inside necrotic region. In VX2 tumor-
bearing rabbit study, 
68
Ga-GP showed higher uptake in heart, liver, bone/joint and blood 
vessels, and lower uptake in brain and tumor than 
18
F-FDG. 
18
F-FDG had higher tumor SUV 
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(7.04) compare to 
68
Ga-GP (3.25). Biodistribution data using 13762 tumor-bearing rats also 
confirmed these findings.  
 
The dynamic tumor uptake of 
68
Ga-GP and 
18
F-FDG in both rats and rabbit animal 
models had very similar results. Both 
68
Ga-GP and 
18
F-FDG showed very quick uptake at 
the first 1 minute before reached plateau. Both uptakes went up again after 5 minutes (
68
Ga-
GP) and 10 minutes (
18
F-FDG) in a slower but steady linear manner. This pattern implied a 
transporter-based imaging tracer pattern. The first one minute quick plateau reflected the 
rapid cell uptake and the saturation of cell membrane transporters (glutamic acid 
transporters for 
68
Ga-GP and glucose transporters for 
18
F-FDG).  After 5 to 10 minutes, the 
uptake went up reflected the consumption of these probes as nature nutrition (glutamic acid 
for 
68
Ga-GP and glucose for 
18
F-FDG).  This result implied 
68
Ga-GP penetrated cell 
membrane through glutamate transporter [90, 92].     
 
In summary, at present, there is no angiogenesis imaging agent that targets both 
vascular endothelial adhesiveness and cellular transporters.  GP interacts with vascular 
endothelial and cellular targets.  GP also has multiple amino and carboxylic groups, which 
allows for anticancer drug conjugates for targeted imaging and therapy. PET imaging studies 
indicated that it is feasible to use 
68
Ga-GP to image tumors. Although 
18
F-FDG had higher 
tumor SUV, 
68
Ga-GP showed different biodistribution and the ability to differentiae tumor 
and necrotic area. In addition, dynamic tumor uptake pattern demonstrated 
68
Ga-GP 
penetrated cell membrane through transporter mechanism. The imaging data obtained from 
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68
Ga-GP not only provide an impact on improving the diagnosis of cancer but also provide a 
basis for internal radionuclide targeted therapy.  
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CHAPTER 6: GP AS A GLUTAMATE TRANSPORTER TARGETING CARRIER 
FOR DRUG DELIVERY 
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6.1. Rationale and Study Design 
GP was designed for tumor targeting drug carrier purpose. In chapters 4 and 5, our 
data demonstrated that GP could be labeled with different radioisotopes for imaging and 
treatment monitoring. In this chapter, efforts have been make to prove of principle that GP-
drug conjugates could target tumor cells, penetrate the cell membrane, prolong tumor 
retention time and reduce off-target toxicity, and ultimately, increase anticancer ability.  
 
As a drug carrier, one of the most important characteristics is the safety of the 
material itself. GP animal acute toxicity studies were conducted in three different species, 
including rat, mouse and rabbit, to investigate the safety range of GP.  
 
To evaluate the tumor targeting abilities of GP-drug conjugates, an in vivo imaging 
study using tumor-bearing rat was conducted. Tumor-to-muscle count density ratios were 
calculated to test the tumor uptake abilities of each GP-drug conjugate. In addition, a 24 
hour imaging after 
99m
Tc-GP-DOX injection was also conducted to investigate the properties 
of prolonged circulation and tumor accumulation.  
 
An In vitro cellular viability assay using MDA-MB-231 human breast cell line and 
cellular fraction assay using 13762 cells were both conducted to evaluate the cytotoxicity 
and intracellular localization of GP-DOX.   
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Finally, to prove of principle, an in vivo tumor growth delay study using GP-DOX 
and DOX in different doses was performed. The absolute growth delay and tumor growth 
curve were calculated to evaluate the efficacy and the toxicity of GP-DOX. 
 
In statistical analysis, the absolute growth delay of DOX and GP-DOX were 
compared using the Student’s t-test.  Differences were considered to be statistically 
significant for a two-tailed p<0.05.   
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6.2. Results 
6.2.1. Pharmacology and Toxicology 
6.2.1.1. Animal Acute Toxicity Studies of GP 
Three species (rat, mouse and rabbit) were used to test the acute toxicity of GP. 
The rat result: effect of GP on blood chemistry in male and female rats is shown in 
Tables 14-17.  GP showed no acute toxicity in rats. Dosages up to 400 mg/kg were well 
tolerated by rats.  The stable compound to be used as an imaging agent in this proposal (10 
mg/patient, 70 kg) is considerably (700-2800 times) less than doses tested (100-400 mg/kg) 
and shown to have no toxicity in rats. 
 
The mouse result: to ascertain acute toxicity findings in different species, the Swiss 
Webster mice (male and female, n=5/gender) were administered GP (1.0 g/kg) and the mice 
was observed for 14 days.  The body weight was weighed every other day.  There was no 
marked differences in body weight changes in the mice tested (Figure 51). 
 
The rabbit result: there were no marked adverse effects on blood chemistry were 
observed.  The blood chemistry data from rabbits is shown in Table 18.  The GP compound 
to be used as an imaging agent in this proposal (10 mg/patient 70 kg) is considerably (1400 
times) less than doses tested in rabbits. 
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Table 14. Effect of GP on blood chemistry in female Fischer 344 rats on Day 3. 
                                                                                        
            
GP                                        _                                                                                    
                                                   
   Saline                    100mg/kg             200mg/kg               400mg/kg 
 ___________________________________________________________________________ 
 
                                 Mean  SD                                            Mean  SD 
 
Bilirubin (mg/dl)      0.37  0.12               0.20  0.00           0.43  0.15             0.33  0.06 
 
Creatine (mg/dl)       0.39  0.03               0.32  0.02           0.45  0.02             0.39  0.01 
 
Blood Urea                17.0  0.26               17.6  0.42           18.8  3.06             18.9  0.29 
Nitrogen (mg/dl) 
 
Glucose (mg/dl)         114  4.0                  144  1.0              107  5.0              179  20.5 
 
SGOT (U/L)               134.7  32.6             85.3  18.6         140.0  16.6             93.3  7.9 
 
SGPT (U/L)               61.0  1.00               51.7  1.2            65.3  6.7                53.9  1.2 
 
Total Protein (g/dl)    6.57  0.04              6.18  0.05          7.20  0.14             6.71  0.01 
___________________________________________________________________________ 
 
  Data are expressed as means  SD for 12 rats (3 rats per dose of GP). The rats are  
  195.0  5g. 
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Table 15. Effect of GP on blood chemistry in female Fischer 344 rats on Day 14. 
                                                                                                    GP                                        _                                                                                    
                                                   
   Saline                    100mg/kg             200mg/kg               400mg/kg 
 ___________________________________________________________________________ 
 
                                 Mean  SD                                            Mean  SD 
 
Bilirubin (mg/dl)      0.37  0.12               0.30  0.00           0.20  0.00             0.20  0.00 
 
Creatine (mg/dl)       0.40  0.02               0.36  0.01           0.35  0.03             0.34  0.02 
 
Blood Urea                20.3  0.12               20.9  0.21           22.8  0.21             20.5  1.46 
Nitrogen (mg/dl) 
 
Glucose (mg/dl)         169  25.5                  107  0.6           166  13.3               115  1.5 
 
SGOT (U/L)               216.0  46.7            125.3  62.1          88.3  9.5              97.3  25.8 
 
SGPT (U/L)               77.0  1.73               61.0  3.5             57.7  1.5               54.7  0.6 
 
Total Protein (g/dl)    6.49  0.05              6.91  0.04           6.30  0.03            6.44  0.01 
___________________________________________________________________________ 
 
  Data are expressed as means  SD for 12 rats (3 rats per dose of GP). The rats are  
  195.0  5g. 
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Table 16. Effect of GP on blood chemistry in male Fischer 344 rats on Day 3. 
                                                                                      
               
GP                                                                                                                            
                                                   
   Saline             100mg/kg             200mg/kg       400mg/kg 
________________________________________________________________________ 
Bilirubin  0.10.0  0.10.0  0.10. 0 0.10.0 
 
BUN    17.01.2 18.11.1 18.30.9 16.91.5 
 
Creatinine  0.7 0.0 0.7 0.0 0.7 0.0 0.7 0.0 
 
Glucose  1706  1637  1609  1658 
 
SGOT   11012  12111  13015  16140   
 
SGPT   515  535  565  567 
 
Total Protein              6.40.3  6.20.5  6.00.7  6.50.3 
__________________________________________________________________ 
   1.  Data are expressed as means + S.D. for 12 rats (3 rats per dose).             
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Table 17. Effect of GP on blood chemistry in male Fischer 344 rats on Day 14. 
                                                                                     
               
GP                                                                                                                           
                                                   
        Saline            100mg/kg             200mg/kg          400mg/kg 
 ___________________________________________________________________________ 
Bilirubin  0.10.0  0.10.0  0.10.0  0.10.0 
 
BUN    16.90.9 17.51.3 18.50.9 17.91.2 
 
Creatinine  0.7 0.0 0.7 0.0 0.7 0.0 0.7 0.0 
 
Glucose  1459  14311  15010  14110 
 
SGOT   12911  11210  12015  11013   
 
SGPT   595  526  555  497 
Total Protein              6.40.3  6.10.5  6.10.4  6.20.4 
___________________________________________________________________ 
   1.  Data are expressed as means + S.D. for 12 rats (3 rats per dose). 
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Figure 51. GP acute toxicity assay was performed in Swiss Webster mice (males and 
females, n=5/gender). 
 
 After intravenous injection with GP 1.0 g/kg, body weight changes were monitored for 14 
days. The average body weight for male and female was 26 g and 22 g, respectively.  The 
result shows no significant body weight changes in both male and female mice over 14 days 
observation.  
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Table 18. Effect of GP
 
on blood chemistry in New Zealand White rabbits (Day 14) 
 
                                                   
   Saline            GP (200mg/kg)              
 
Bilirubin  0.10.0  0.10.0  
 
BUN    18.00.9 22.51.0  
 
Creatinine  0.7 0.0 1.18 0.0  
 
Glucose  1256  1166  
  
SGOT   12310  12012    
 
SGPT   527  545   
 
Total Protein              6.40.6  5.30.3 
___________________________________ 
   1.  Data are expressed as means + S.D. for 2 rabbits. 
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6.2.1.2. Scintigraphic Imaging Studies with GP-drug Conjugates 
Four GP-drug conjugates were synthesized, including GP-methotrexate (GP-MTX), 
GP-folate (GP-FOL), GP-doxorubicin (GP-DOX) and GP-pamidronate (GP-PAM).  
Imaging results demonstrated that GP-drug conjugates accumulated in the tumor (Figure 
52).   
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Figure 52. Planar scintigraphy of 
99m
Tc-Chi and 
99m
Tc-GP-drug conjugates in breast tumor-
bearing rats. 
 
Data showed that 
99m
Tc-GP and its conjugates have faster uptake than 
99m
Tc-Chi. The 
numbers are tumor to muscle count density ratios (counts/pixel) at 60-180 minutes. MTX:  
methotrexate; FOL: folate; DOX: doxorubicin; PAM: pamidronate. 
  
  - 
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6.2.1.3. In Vitro Cellular Toxicity Assay (MTT assay) 
 To determine the cytotoxicity of GP-DOX, an in vitro cellular toxicity assay was 
conducted using MDA-MB-231 cells treated with different doses of DOX, GP-DOX and GP 
(as a control).  As expected, DOX showed a dose dependent cytotoxicity as early as 24 
hours after treatment (Figure 53). GP-DOX, on the other hand, showed a mild cytotoxicity 
on 24 hours but a strong cytotoxicity on 48 hours. This data indicated that GP-DOX has a 
similar cytotoxicity to DOX with slow release pattern.   
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Figure 53. Cellular viability assay of GP-DOX. 
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6.2.1.4. In Vitro Cellular Fraction Assay 
To determine the distribution pattern of 
99m
Tc-GP-DOX within the cells, NE-PER 
extraction reagents were used for stepwise isolation of cytoplasmic and nuclear extracts 
from breast cancer cells.  20% of intracellular 
99m
Tc-GP-DOX was located in cell nucleus; 
whereas 80% was in the cytosol (Figure 54). 
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Figure 54. In vitro cellular fraction assay of 
99m
Tc-GP-DOX  
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6.2.1.5. Scintigraphic Imaging Studies 
To demonstrate the retention of 
99m
Tc-GP-DOX in breast tumor cells, breast tumor-
bearing rat were administered with 
99m
Tc-GP-DOX (300 µCi/rat, 1.0 mg physical amount, 
iv.)  Scintigraphic images, using a gamma camera equipped with low-energy, parallel-hole 
collimator, were obtained after 2 and 24 hours. Tumor-to-muscle count density ratios 
increased from 4.1 at 2 hours to 5.8 at 24 hours (Figure 55). This result indicated that GP 
prolonged the circulation time and tumor retention time of DOX. 
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Figure 55. 2 and 24 hours planar images of breast tumor-bearing rats with 
99m
Tc-GP-DOX. 
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6.2.1.6. In Vivo Tumor Growth Delay Study 
 Tumor growth delay study was conducted in MDA-MB-231 tumor-bearing nude 
mice. Two different doses of DOX (10 mg and 20 mg/kg), four doses of GP-DOX (100 mg-
600 mg/kg) and normal saline were injected intravenously to animals through tail vain 
(single dose). DOX showed high tumor growth delay ability (Figure 56). However, all mice 
injected with DOX died on day 11 (DOX: 20 mg/kg) and day 21 (DOX: 10 mg/kg) after 
injection suggested the toxicity of DOX (Figure 57). GP-DOX, on the other hand, showed 
similar life length to the control animals with similar tumor growth delay ability to DOX 
treated animals in the first week after injection. Absolute growth delay was calculated by 
using the time (in days) for tumor growth from 70 to 500 mm
3
 minus the time required for 
the control group tumors to reach the same size (70 to 500 mm
3
) (Figure 58). Three doses of 
GP-DOX showed significant growth delay compared to control group (200 mg/kg: 
2.11±0.89 days, p<0.024; 300 mg/kg: 3.05±1.28 days, p<0.002; 600 mg/kg: 3.70±1.59 days, 
p<0.004). DOX at10 mg/kg also showed significant absolute growth delay as 3.10±2.11 
days, p<0.004. Unfortunately, DOX at 20 mg/kg was too toxic and all animals died before 
the tumors reached 500 mm
3
. This result indicated that GP-DOX showed decreased toxicity 
with appropriate efficacy.  
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Figure 56. Tumor growth delay of GP-DOX and DOX. 
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Figure 57. Survival curve of GP-DOX and DOX.  
 
The average survival time was measured by calculating the lifetime of mice (until death) 
after different treatments. Mice in the GP-DOX600-0.4 group showed a longer average 
survival time than those in the other groups. 
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Figure 58. Absolute growth delay of GP-DOX and DOX.  
 
Absolute tumor growth delay (aGD) under treatment with DOX alone and GP-DOX 
compared with treatment for tumors with mean ± S.D. A more than additive treatment effect 
was observed in GP-DOX.  
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6.3. Discussion  
In the GP acute toxicity assay, all three tested animal species showed no significant 
changes in blood chemistry or body weight compared to control group. In rat, the injection 
doses were 100 mg, 200 mg and 400 mg/kg single dose intravenous injection. Considering 
the practical human dose (10 mg/human, 70kg), these doses were 700-2,800 times higher 
than human dose (based on weight-to-weight calculation). In rabbit, 200 mg/kg of GP was 
injected.  this was 1,400 times higher than the human dose. The acute toxicity results 
demonstrate that GP is a safe material for injection. In mouse, body weight, instead of blood 
chemistry, was measured and recorded to evaluate the safety of GP. There was no 
significant body weight (15%) change after two weeks of injection.    
 
The in vivo imaging study of 
99m
Tc-labeled GP-drug conjugates showed that all 
testing GP-drug conjugates accumulated in tumor and the accumulations were increased by 
time. The highest tumor-to-muscle density count ratio was for 
99m
Tc-GP followed by 
99m
Tc-
GP-MTX and 
99m
Tc-GP-FOL. All testing compounds showed tumor-to-muscle ratio greater 
than 3.5 (at 3 hour imaging). However, the biodistribution of each testing compound was 
slightly different, which reflected the different chemical and physiological properties of each 
GP-drug. For instance, 
99m
Tc-GP-PAM showed low liver uptake but high bone uptake. Since 
pamidronate itself is a bone seeking agent, conjugation with GP preserved part of its original 
property. Furthermore, in the prolonged imaging study (24 hours after injection), 
99m
Tc-GP-
DOX showed prolonged retention in tumor (tumor-to-muscle ratio reached 5.8; 4.1 at 2 
hours). This data indicated that GP can not only bring drugs to target tumor, but it can also 
help drugs remain in the tumor.  
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The in vitro cellular viability assay demonstrated another important ability of GP in 
polymeric drug delivery. The data showed that at the same DOX equivalent concentration, 
GP-DOX killed cells almost as much as DOX at 48 hour but not 24 hours. At 24 hours, GP-
DOX only showed half to one-third cytotoxicity. This data indicated that GP-DOX 
demonstrated a slow-release pattern in cell culture media.  In addition, from the in vitro 
cellular fraction assay, about 20% of 
99m
Tc-GP-DOX located inside the cell nucleus, 
whereas 80% of 
99m
Tc-GP-DOX was in cytosol.  In the similar cellular fraction study, we 
found 
99m
Tc-GP located 40% in cell nucleus and 60% in cytosol. This difference confirmed 
our earlier observation that GP-drug conjugation changed the properties of both GP and 
drugs.   
 
To evaluate the efficacy of GP-DOX, an in vivo tumor growth delay study was 
conducted. This assay measured the response of tumor to drug treatment in vivo. The 
absolute growth day data showed GP-DOX at 200 mg/kg had 2 days of absolute growth 
delay. Moreover, GP-DOX at 300 mg and 600 mg/kg showed similar absolute growth delay 
(3 days and 3.7 days in average, respectively) with DOX at 10 mg and 20 mg/kg (3 days). In 
the tumor growth delay studies, although 10 mg and 20 mg/kg of DOX injection showed 
greatest tumor growth delay, testing animals died in the middle of the study (day 63 and day 
56, respective). On the other hand, GP-DOX at 300 mg and 600 mg/kg showed slow tumor 
growth with testing animals remaining alive until day 65 (end of study). This result 
demonstrated the efficacy and low toxicity of GP-DOX. 
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To prove the principle that GP can be used for drug conjugation, methotrexate, folate, 
doxorubicin and pamidronate were conjugated with GP. The conjugation rates were above 
28.7% (w/w) measured by UV spectroscopy method. GP-DOX was selected for the in vitro 
and in vivo evaluation for the highest conjugation rate (33.5%, w/w) and the broad 
applications in cancer treatment. Doxorubicin is used in the treatment of cancers such as 
acute leukemia, lymphomas, breast carcinoma, sarcomas, bronchogenic (lung) carcinoma 
[139-141].  However, limited solubility and target non-selectivity of DOX leads to damage 
of healthy tissues, with particularly severe injury in myocardial tissue [142]. In other words, 
DOX may cause cardiotoxicity in a dose-dependent manner, which is the major drawback 
and limiting factor for its application [143]. By conjugating with GP, the solubility of DOX 
is highly increased. In addition, GP increases tumor uptake of DOX; hence, the target non-
selectivity of DOX is also reduced. Furthermore, the slow release pattern and longer tumor 
retention time both increases the therapeutic index of DOX, and potentially, decreases the 
cardiotoxicity. 
 
In summary, in vitro and in vivo data along with imaging findings indicate that GP is 
a potential theranostic carrier with active and passive tumor targeting abilities, circulation 
time increasing ability and slow release ability.  
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CHAPTER 7: SUMMARY, SIGNIFICANCE AND FUTURE DIRECTIONS 
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7.1. Summary 
The purpose of this study was to design, synthesize and develop novel transporter 
targeting agents for image-guided therapy and drug delivery. Two agents, N4amG and GP, 
were synthesized for nucleoside transporter and amino acid transporter targeting, 
respectively. We hypothesized that radiolabeled N4amG and GP can actively penetrate the 
cell membrane through transporters. Furthermore, the retention of radiolabeled N4amG and 
GP in tumors will allow specific assessment of tumors. Lastly, I proposed that GP-DOX 
conjugates will be more specific and less toxic than DOX in tumor treatment. Therefore, in 
the first specific aim, N4amG and GP were synthesized and radiolabeled with 
99m
Tc and 
68
Ga. The chemical and radiochemical purities as well as radiochemical stabilities of 
radiolabeled N4amG and GP were tested. In vitro stability results showed both 
99m
Tc-
N4amG and 
99m
Tc-GP are stable up to 6 hours, whereas 
68
Ga-GP is stable at least 2 hours. In 
vitro cell culture studies from Specific Aim 2 then confirmed radiolabeled N4amG and GP 
can penetrate the cell membrane through nucleoside transporters and amino acid 
transporters, respectively. Up to 40% of intracellular 
99m
Tc-N4amG and 
99m
Tc-GP locate in 
cell nucleus after 2 hours incubation. Cell sorting assay revealed 
99m
Tc-N4amG is a cell 
cycle S phase-specific agent. The uptake of
 99m
Tc-GP in pre- and post- paclitaxel treated 
cells showed significant differences, which demonstrated the ability of 
99m
Tc-GP in 
chemotherapy treatment monitoring. In Specific Aim 3, radiolabeled N4amG and GP were 
tested in vivo using tumor-bearing animal models. 
99m
Tc-N4amG showed tumor-to-muscle 
ratios up to 5 at 4 hour imaging. Both 
99m
Tc-labeled agents showed decreased uptake after 
paclitaxel treatment. IHC results demonstrated that the uptake of 
99m
Tc-N4amG is correlated 
to Ki-67 staining. In tumor/inflammation dual-bearing animal studies, both 
99m
Tc-N4amG 
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and 
99m
Tc-GP showed differentiation between tumor and inflammation. In addition, 
68
Ga-GP 
was compared to 
18
F-FDG in rabbit PET imaging studies. Although 
68
Ga-GP had lower 
tumor SUV, 
68
Ga-GP showed different biodistribution and similar tumor uptake dynamics to 
18
F-FDG. Finally, for a proof of concept that GP can be a potential drug carrier for cancer 
theranostics, selected drugs were conjugated to GP. Imaging studies demonstrated that GP-
drug conjugates increased tumor uptake as a function of time. GP-DOX showed a slow-
release pattern in the in vitro cytotoxicity assay and showed anti-cancer efficacy with 
reduced toxicity in the in vivo tumor growth delay study. Collectively, these data reveal that 
N4amG and GP are both transporter targeting agents. Radiolabeled N4amG can be used for 
tumor cell proliferation assessment. GP is a potential technology platform for image-guided 
therapy and drug delivery. 
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7.2. A Novel Nucleoside-based Functional Radiotracer 
Nucleoside analogs have long been an attractive source for imaging probe designing. 
Many radiolabeled nucleoside analogs have been reported. Most of those radiolabeled 
purine and pyrimidine were probes for imaging reporter gene expression, especially for 
herpes simplex virus type 1 thymidine kinase (HSV1-tk) expression. For instance, 
pyrimidine derivatives: 2'-fluoro-2'-deoxy-5-iodo-1-ß-D-ribofuranosyl-uracil (FIRU), 2'-
fluoro-2'-deoxy-5-iodo-1-ß-D-arabinofuranosyluracil (FIAU), 2'-fluoro-2'-5-methyl-1-ß-D-
arabinofuranosyluracil
 
(FMAU), 2'-fluoro-2'-deoxy-5-iodovinyl-1-ß-D-ribofuranosyl-uracil
 
(IVFRU), and acycloguanosine derivatives: 9-[4-hydroxy-3-(hydroxy-methyl)butyl]guanine 
(PCV), 
 
9-[(2-hydroxy-1-(hydroxymethyl) ethoxy)methyl]guanine
 
(GCV) [144-149], and 
other 
18
F-labeled acycloguanosine derivatives: 8-fluoro-9-[4-hydroxy-3 (hydroxymethyl) 
butyl]guanine
 
(FPCV) [146, 147] , 8-fluoro-9-[(2-hydroxy-1-
(hydroxymethyl)ethoxy)methyl]guanine (FGCV) [144, 148], 9-[4-fluoro-3-
(hydroxymethyl)butyl]guanine
 
(FHBG) [150, 151], 9-[3-fluoro-1-hydroxy-2-
propoxymethyl]guanine
 
(FHPG) [152, 153] have all been developed as probes for imaging
 
wild-type and mutant [146] HSV1-tk expression. The reason for targeting HSV1-tk is 
mainly for reporter gene expression assessment. This reporter gene imaging technology may 
be used in the future for transgene therapy monitoring and assessment. However, the utility 
of using reporter gene imaging depends mostly on the delivery method of the reporter gene 
in vivo. Each delivery method, namely adenoviral vector, liposome and direct injection, has 
its own limits. Therefore, the application of using radiolabeled purine or pyrimidine for 
HSV1-tk imaging is limited.  Not to mention that the radiolabeled purine or pyrimidine used 
for HSV1-tk imaging is basically imaging reporter gene expression not imaging cell 
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proliferation.  Other radiolabeled nucleoside analogs which are used for cell proliferation 
assessment, such as 
11
C-thymidine, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-[methyl-
11
C]thymine (
11
C-FMAU), deoxyuridine (UdR; I, Br or F labeled) and 
18
F-FLT, have their 
own limitations. 
11
C-labeled compounds lack of clinical application due to short radioactive 
half-life (20.3 minutes). In addition, 
11
C-thymidine can be metabolized in human body very 
rapidly. 
124
I-, 
76
Br- or 
18
F-labeled UdR suffers from the rapid dehalogenation in vivo [154]. 
As for 
18
F-FLT, as mentioned in Chapter 1, low DNA incorporation and complex chemistry 
with poor yield limit its application.  All in all, although many radiolabeled nucleoside 
analogs have been developed for imaging, no agent has yet been approval for clinical use in 
patients.  
 
Our data demonstrated that N4amG has certain characteristics beyond current 
nucleoside-based radiotracers for imaging cell proliferation. First, N4amG resists cellular 
nucleoside metabolism. N4amG is a derivative of guanosine, which is one of the essential 
nucleosides for both DNA and RNA. Different from guanosine, however, N4amG has a 
carbon chain instead of a deoxyribose. Similar to penciclovir metabolism [54], this carbon 
chain makes N4amG structurally similar to guanine, but resistant to purine nucleoside 
phosphorylase (PNP), which metabolizes guanosine to guanine.  The PNP resistance 
increases the chance of N4amG being phosphorylated and, as a result, increases the DNA 
incorporation. Secondly, cold N4amG drug substance can be synthesized in large amounts 
with an appropriate yield. The radiochemical yield and radiochemical purity of 
99m
Tc-
N4amG and 
68
Ga-N4amG are both greater than 95%. The high radiochemical yield and 
purity should be attributed to chelation chemistry, which has been mentioned in Chapter 1. 
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Another advantage of using chelation chemistry is the capacity of labeling with different 
radioisotopes for different purposes in single cold agent, in this case, N4amG. Labeling 
ability of 
99m
Tc and 
68
Ga has been tested in this study for imaging purposes. Other 
radioisotopes, such as 
188
Re, 
177
Lu and 
90
Y are potential candidates to label with N4amG for 
radiation therapy purposes. Furthermore, N4amG has the potential to be produced, delivered 
and stored as a cold kit product. Before usage, N4amG can then be labeled with desired 
radioisotopes produced onsite from in-house generators. Moreover, our in vitro results 
revealed the high cellular uptake, nucleus-directed, cell cycle S phase-preferred properties of 
radiolabeled N4amG. Finally, from imaging results, both tumor-to-muscle ratio and tumor-
to-inflammation ratio indicated the tumor specificity of
 99m
Tc-N4amG. 
 
The logical next step of this project will be in two directions:  the improvement of 
N4amG chemistry and the more detailed study of N4amG uptake and accumulation 
mechanisms. From a medicinal chemistry point of view, the amide linkage (peptide bond) 
between bifunctional chelator (N4) and lead compound (penciclovir) is relatively fragile. It 
is stronger than an ester linkage, which could be rapidly hydrolyzed by esterase in vivo, but 
it still can be hydrolyzed by protease, such as trypsin. An amide linkage is suitable for 
diagnostic agents because of its relatively faster elimination time in vivo, which will reduce 
the radiation absorption dose for patient and will increase imaging quality by reducing the 
background noise in the image. For therapeutic usage, a carbon-nitrogen bond is preferred 
because it gives resistance to proteases resulting in longer circulation time. Attempts have 
been made to synthesize N4-Guan and EC-Guan with carbon-nitrogen bond between 
chelators and lead compound.   Unfortunately, low to zero overall yield made these attempts 
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fail. I have discussed possible reasons of the failure in Chapter 3; here, I want to focus on 
the solution. One of the possible reasons of the failure is the bulky protection group blocks 
the space causing unfavorable SN2 reaction condition. A possible solution is to exchange the 
bulky methoxytrityl group with a smaller protection group, such as BOC-group. By reducing 
the spatial barrier, it could possibly increase the yield.  
 
With reference to N4amG uptake mechanism, although we have shown the uptake of 
99m
Tc-N4-Guan is through NTs, which one of hNTs is responsible for the uptake becomes 
the next question. hNT protein families have been discussed in Chapter 3. First of all, the 
expression of hNTs in the testing cell lines should be determined.  Since there are no 
commercially available antibodies to detect hNTs, real-time PCR is the best way to analyze 
the hNTs expression in cell.  Primers and probes of hNTs as listed in Table 19 are acquired 
from known literature [36]. To determine which hNTs is/are responsible 
99m
Tc-N4amG 
uptake, an inhibition study can be performed using hNT specific inhibitors with Na
+
-positive 
buffer and Na
+
-negative buffer. This design is based on the fact that hENTs are sodium-
independent and hCNTs are sodium-dependent. Furthermore, the intracellular 
99m
Tc-N4amG 
needs to be further phosphorylated to become nucleotide analogue (triphosphate) in order to 
involve in DNA/RNA synthesis. Unphosphorylated 
99m
Tc-N4amG could be transported out 
of cells through the same transporter system. Phosphorylation of penciclovir by a cellular 
deoxyguanosine kinase has been reported [54]. It is very crucial to understand whether the 
same cellular enzyme can phosphorylate 
99m
Tc-N4amG in vivo, and thus, it helps radiotracer 
accumulate in the cells. Furthermore, only single cell line (13762, rat breast adenocarcinoma 
cell) was used in both in vitro and in vivo studies. Although 
99m
Tc-N4amG showed high 
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cellular uptake and tumor-to-muscle count density ratios in our testing models, it may just be 
a cell type-specific phenomenon. It is necessary to use a second and/or a third cell line to 
confirm the findings.  A549 cells can be used in future study because it is one of the few cell 
lines that express almost all hNTs, including hCNT2, which is known to have the capacity in 
transporting purines in vivo. In addition, A549 cell line was derived from a lung carcinoma, 
and 
18
F-FLT-PET has been reported to have high potential utility in lung cancers [155]. 
Moreover, MCF-7, U251 and Capan-2 cells (derived from a breast adenocarcinoma, 
glioblastoma and pancreatic carcinoma, respectively) are potential candidates because these 
cell lines express high level of hNTs [36]. 
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Table 19. Real-time PCR probe and primer concentrations and sequences. 
 
 
203 
 
7.3. A Novel Polymeric Drug Delivery Platform for Cancer Theranostics 
Despite the fact that hundreds of drugs have been proved to kill cancer cells, cancer 
still remains the population’s greatest health fear. One of the main reasons is cancer’s nature 
of heterogeneity and adaptation. A single agent can only kill a part of cancer for a certain 
amount of time. To overcome this therapeutic limitation, it is necessary to develop a 
technology platform with the abilities to predict cancer treatment plan, deliver appropriate 
drug(s) to the right site, monitor treatment response and conjugate to as many as different 
drugs.  From this point of view, a polymeric (multi-) drug delivery system with imaging 
capacity is one of a few qualified technology candidates.   
 
Theoretically, cancer theranostics using polymeric drug delivery technology 
approach seems promising. Practically, however, there are many barriers from the laboratory 
bench to the patient’s bedside. In order to be used in humans, certain issues of the polymeric 
carrier itself need to be first clarified. These issues include toxicity, biocompatibility, 
elimination routes, clearance rate (biological half-life), off-target distribution, 
pharmacokinetics and targeting efficiency [62]. 
 
GP was typically designed for polymeric cancer theranostic approach. This study 
investigated and revealed chemical and physiological properties of GP for clinical use. 
Multi-carboxylic and amino functional groups not only help GP to stably chelate 
radioisotopes for imaging, but they also provide wild range of anti-cancer drug conjugation. 
The combination of chitosan and glutamate peptide brings GP both abilities to target tumor 
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angiogenesis and penetrate tumor cell membrane through glutamate transporter. Drugs are 
given the similar tumor targeting ability by conjugating with GP. The safely and 
biocompatibility of GP extends its clinical application. 
 
In cancer theranostic technology development, another barrier that bothers scientists 
is the different dosage requirements for both diagnostic and therapeutic properties of these 
agents. As McCarthy pointed out in a theranostic nanoparticles study based on co-
encapsulating of 
18
F and DOX [156],  since the usual working dose for 
18
F imaging is about 
0.5–1.0 μg/kg body weight whereas for DOX is about 2 mg/kg, it is highly possible that the 
patient receives an excess of  maximum allowable 
18
F exposure with not enough  DOX 
therapeutic dose. Unlike nanoparticles, GP overcomes this problem simply by using 
different physical amounts in imaging and in therapy. Moreover, our data demonstrated GP-
drug conjugates can be labeled with 
99m
Tc for imaging. 
 
The development of hybrid multimodality imaging technology is in progress. 
SPECT/CT and PET/CT are currently available.  Even SPECT/MR and PET/MR are under 
development as they provide functional and anatomical information with less ionizing 
radiation [4]. Therefore, polymeric cancer theranostic technologies carrying multiple 
imaging probes, including the combination of PET, fluorescent and MRI probes for 
multimodality imaging are being developed [62, 157]. GP can be labeled with both 
99m
Tc 
and 
68
Ga for SPECT and PET imaging, respectively. Our preliminary results using 
gadolinium-ethylenediaminetetraacetic acid conjugated chitosan (Gd-EDTA-chitosan) 
showed increased tumor visibility in pig MR imaging. To evaluate the possible toxicity of 
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Gd and to expend the future application, more evaluation on Gd-EDTA-chitosan regarding 
safety and efficacy are in progress. 
 
Based on the facts that chitosan shows high affinity to the vascular endothelial cells 
and glutamate peptide can penetrate cell membranes, radiolabeled GP can be a potential 
imaging probe for tumor angiogenesis [90, 92]. Tumor angiogenesis not only provide 
nutrient and oxygen support for tumor growth, but also facilitate tumor metastasis.  The 
vascular density, in certain tumors, can be used as a prognostic indicator for metastatic 
potential. In other words, a tumor with higher vascular density has a higher chance of 
metastasis [158].  Measurement of angiogenesis in solid tumors can be used as a biomarker 
for tumor progression, metastasis and prognosis [159, 160]. Since there is no angiogenesis 
imaging agent focused on both vascular endothelial adhesiveness and cellular target, 
radiolabeled GP has the potential to access tumor angiogenesis through a dynamic, non-
invasive way. As a result, GP images may become a useful tool for the assessment of tumor 
progression, metastasis and prognosis. 
 
The Enhanced Permeability and Retention (EPR) effect is known as one of the 
mechanisms for macromolecular drugs to target solid tumors. It was first reported in 1986 
[161]. To ensure a sufficient supply of oxygen and nutrients for rapid growth, most solid 
tumors produce large amounts of various vascular permeability factors and have defective 
blood vessels. As a result, most solid tumors exhibit enhanced vascular permeability [162-
164]. The unique defective architecture nature of tumor blood vessels facilitates 
macromolecules transport into tumor tissues. The EPR effect is a molecular weight-
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dependent phenomenon.  It has been reported that the EPR effect benefits macromolecules 
with molecular weights large than 40 kDa to accumulate in tumor tissues [165].  The 
molecular weight of GP was 6,000-9,000 Da. Therefore, the tumor targeting ability of GP 
may not directly caused by the EPR effect. GP was designed for cancer theranostic 
purposes. Macromolecules (>40 kDa) may not suitable for nuclear imaging due to the slow 
blood clearance rate and the high background noise in the image. As discussed in section 
5.3., the optimal molecular weight range (6,000-9,000 Da) facilitated GP for both tumor 
vascular and intracellular targeting. 
 
Kit formation is one of the advantages of chelation chemistry-based radiotracers. 
Many clinically used 
99m
Tc-labeled radiotracers are commercially available in single kit 
form. The formulation of each kit was approved by FDA and listed on the United States 
Pharmacopeia (USP). Take DTPA kit (Jubilant DraxImage Inc., Quebec, Canada) as an 
example, 
99m
Tc-DTPA is usually used in clinic for renography. The chemical ingredients in 
a single kit include DTPA 20 mg, p-aminobenzoic acid 5 mg, calcium chloride dihydrate 
3.73 mg and stannous chloride dihydrate 0.25mg. The cold kit should be stored at 2 ℃ to 25 
℃. To prepare 99mTc-DTPA for injection, up to 500 mCi of 99mTc is added to the vial 
through a syringe. After 15 minutes, 
99m
Tc-DTPA is ready to use for the next 12 hours. 
Several efforts have been made to produce GP single kit. Stannous chloride is one of the 
essential ingredients, which is responsible for pertechnetate reduction. Anti-oxidant agents 
such as ascorbic acid are considered to keep the reduction ability of stannous chloride. Other 
agents may also add to the formula for various purposes including osmolarity maintenance 
and image improvement. During the preparation of kit solution, the pH value and oxygen 
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content are important and need to be well controlled. A continuous nitrogen gas bubbling is 
highly recommended. After filter the solution through a 0.22 µm sterile filter, solution is 
dispensed in the vials and ready for lyophilization. The water content and storage 
temperature are also crucial for stabilizing kit product. As a future direction, there is still 
room for improvement of GP kit formulation. 
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7.4 . Conclusion 
In conclusion, the present study has discovered and developed two novel agents, 
N4amG and GP. Due to the need of cell proliferation imaging tracer and theranostic 
technology platform, both agents appear extremely promising.  Radiolabeled N4amG has the 
potential to target proliferating cells; as a result, it can better differentiate between 
proliferating cells from resting, necrotic or apoptotic cells, as well as tumor from 
inflammation. In clinical application, N4amG has the potential to monitor treatment 
response and to detect tumor with higher accuracy. Furthermore, the convenient 
radiolabeling chemistry and cost-effectiveness make N4amG more accessible to a wide 
range of patients. Radiolabeled GP shares similar radiochemical convenience and cost-
effectiveness due to chelation chemistry and less expensive radioisotopes.  Our data 
indicated GP has the ability to target tumor in vitro and in vivo. By conjugating GP with 
anticancer drugs, great benefits will be achieved including longer circulation time, less off-
target effect, slow release pattern and better solubility. In other words, GP can increase the 
therapeutic index of cancer chemotherapy drugs. In clinical application, radiolabeled GP 
may be used for treatment planning. With high tumor uptake of GP, patients may then be 
treated with GP-drugs. Treatment responses can be evaluated by either radiolabeled GP or 
N4amG.  
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